<rss version='2.0'>

                    <channel>

                    <title><![CDATA[Rhabdomyosarcoma]]></title>

                    <link>https://www.benthamscience.com</link>

                    <description>

                    RSS Feed for Disease Wise Article | BenthamScience

                    </description>

                    <generator>EurekaSelect (+http://eurekaselect.com)</generator>

                    <pubDate>Tue, 21 Apr 2026 07:02:23 +0000</pubDate>

                    <image>

                    <title><![CDATA[Rhabdomyosarcoma]]></title>

                    <url>https://www.benthamscience.com</url>

                    <link>https://www.benthamscience.com</link>

                    </image><item><title><![CDATA[PF-04449913 Inhibits Proliferation and Metastasis of Colorectal Cancer Cells by
Down-regulating MMP9 Expression through the ERK/p65 Pathway]]></title><link>https://www.benthamscience.comarticle/134613</link><description><![CDATA[<P>Introduction: Colorectal cancer remains a life-threatening malignancy with increasing morbidity and mortality worldwide. Therefore, new and effective anticolorectal cancer therapeutics are urgently needed. <P> Methods: In this study, we have studied the anti-tumor properties and potential mechanisms of PF-04449913. Colorectal cancer cell viability was reduced by PF-04449913 in a dose-dependent manner. The migration and invasion ability of malignant colon cells were attenuated by the drug, as demonstrated by the Transwell test. Moreover, PF-04449913 repressed the phosphorylation levels of ERK and other proteins, and the expression levels of MMP9. The anti-tumor effects of the drug <i>in vivo</i> were demonstrated in BALB/c-nude mice models, and PF-04449913 inhibited the malignant phenotype of colorectal cancer cells, including reduction of tumor size and promotion of apoptosis. At the molecular level, PF-04449913 induced a significant decrease in ERK and p65 protein phosphorylation levels and inhibited MMP9 protein expression. <P> Results: Both <i>in vivo</i> and in vitro results showed PF-04449913 to demonstrate antitumor effects, which have been proposed to be mediated through blockade of the ERK/p65 signaling pathway, and subsequent repression of MMP9 expression. <P> Conclusion: Our study provides a new perspective on the potential clinical application of PF-04449913 in the treatment of colorectal cancer.</P>]]></description> </item><item><title><![CDATA[Value of Multimodal Diffusion-weighted Imaging in Preoperative Evaluation of
Ki-67 Expression in Endometrial Carcinoma]]></title><link>https://www.benthamscience.comarticle/133564</link><description><![CDATA[<p>Purpose: To investigate the value of multimodal diffusion weighted imaging (DWI) in preoperative evaluation of Ki-67 expression of endometrial carcinoma (EC). <p> Materials and Methods: Patients who had undergone pelvic DWI, intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) sequence MRI scan before surgery were retrospectively enrolled. Single index model, double index model, and DKI were used for post-processing of the DWI data, and the apparent diffusion coefficient (ADC), real diffusion coefficient (D), pseudo diffusion coefficient (D*), perfusion fraction (f), non-Gaussian mean diffusion kurtosis (MK), mean diffusion coefficient (MD) and anisotropy fraction (FA) were calculated and compared between the Ki-67 high (≥50%) and low (&#60;50%) expression groups. <p> Results: Forty-two patients with a median age of 56 (range 37 - 75) years were enrolled, including 15 patients with a high Ki-67 (≥50%) expression and 27 with a low Ki-67 (&#60;50%) expression. The MK (0.91 ± 0.12 vs. 0.76 ± 0.12) was significantly (P<0.05) higher while MD (0.99 ± 0.17 vs. 1.16 ± 0.22), D (0.55 ± 0.06 vs. 0.62 ± 0.08), and f (0.21 vs. 0.28) were significantly (P&#60;0.05) lower in the high than in the low expression group. The combined model of MK, MD, D, and f-values had the largest area under the curve (AUC) value of 0.869 (95% CI: 0.764-0.974), sensitivity 0.733 and specificity 0.852, followed by the MK value with an AUC value 0.827 (95% CI: 0.700-0.954), sensitivity 0.733 and specificity 0.815. <p> Conclusions: IVIM and DKI have certain diagnostic values for preoperative evaluation of the EC Ki-67 expression, and the combined model has the highest diagnostic efficiency.</p>]]></description> </item><item><title><![CDATA[Intravoxel Incoherent Motion Diffusion-weighted MRI Assessing the Effect of
the Vascular Disrupting Agent CA4P on VX2 Liver Tumors in Rabbits]]></title><link>https://www.benthamscience.comarticle/130009</link><description><![CDATA[<p>Objective: This study aimed to assess the response of combretastatin-A4-phosphate (CA4P) in rabbit VX2 liver tumors using intravoxel incoherent motion diffusion-weighted MRI (IVIM DW-MRI). <p> Methods: Forty rabbits with implanted VX2 liver tumors underwent baseline MRI and were then given 10 mg/kg CA4P (n=20) or saline (n=20). After 4 h, 10 rabbits from each group underwent an MRI examination and were then sacrificed. The remaining rabbits underwent MRI after 1, 3, and 7 days and were then sacrificed. Liver samples were processed for H&E and immunohistochemical staining. IVIM parameters (D, f, D*) were compared in the treatment and control groups, and the correlations of IVIM parameters with microvascular density (MVD) were determined. <p> Results: At 4 h, the two treatment groups had significantly different f and D* values (p<0.001), and these values were at their minimum in the treatment group. The treatment group had moderate correlations between MVD and f at 4 h (r=0.676, p=0.032) and 7 days (r=0.656, p=0.039) and with D* at 4 h (r=0.732, p=0.016) and 7 days (r=0.748, p=0.013), but no correlation was reported between MVD and f or D* in the control group (all P>0.05). <p> Conclusion: IVIM DW-MRI is a sensitive imaging technique. It successfully evaluated the effect of CA4P on VX2 liver tumors in rabbits. The f and D* values correlated with MVD at 4 h and 7 days after using CA4P, indicating that these parameters have the potential to be used as indicators of tumor angiogenesis after treatment.</p>]]></description> </item><item><title><![CDATA[Malignant and Benign Head and Neck Tumors of the Pediatric Age: A Narrative Review]]></title><link>https://www.benthamscience.comarticle/137392</link><description><![CDATA[Malignant tumors of the head and neck are rare in children, but it is important to know these lesions and identify them early in order to have a good outcome for these patients. Benign lesions of the head and neck are much more frequent and have an excellent prognosis. For this reason, it is necessary to recognize the warning signs and symptoms and understand when to refer the patient to a reference center for the treatment of these pathologies. The clinical presentation of both benign and malignant lesions in children may be similar as usually, both categories have compressive effects. This confirms the fact that the clinical diagnosis is not sufficient and always requires instrumental investigations and biopsies. In this narrative review, we analyzed both malignant lesions such as lymphoma, rhabdomyosarcoma, thyroid tumors, salivary gland tumors, neuroblastoma, and nasopharyngeal carcinoma, and benign ones such as cystic dermoid teratoma, hemangioma, juvenile angiofibroma and fibrosis dysplasia. Indeed, we set out to discuss the most common lesions of this site by evaluating their characteristics to highlight the differentiation of malignant tumors from benign lesions and their correct clinical-therapeutic management. A literature search was carried out in the PubMed and Google Scholar databases to identify all narrative reviews addressing malignant and benign head and neck tumors of the pediatric age. In conclusion, the care of children affected by head and neck benign lesions and malignancy must be combined and multidisciplinary. It is essential to recognize the diseases early in order to differentiate and intervene as soon as possible for the correct clinical-therapeutic management.]]></description> </item><item><title><![CDATA[Expression of Circulating miR-21 and -29 and their Association with
Myocardial Fibrosis in Hypertrophic Cardiomyopathy]]></title><link>https://www.benthamscience.comarticle/138201</link><description><![CDATA[<P>Background: Hypertrophic Cardiomyopathy (HCM) is characterized by myocardial hypertrophy, fibrosis, and sarcomeric disarray. <P> Objective: To evaluate the expression levels of circulating miR-21 and -29 in patients with HCM and their association with clinical characteristics and myocardial fibrosis. <P> Methods: In this case-control study, 27 subjects with HCM, 13 subjects with hypertensive cardiomyopathy, and 10 control subjects were enrolled. Evaluation of patients’ functional capacity was made by the six-minute walk test. Echocardiographic measurements of left ventricle systolic and diastolic function were conducted. Cardiac magnetic resonance late gadolinium enhancement (LGE) -through a semiquantitative evaluation- was used in the assessment of myocardial fibrosis extent in HCM patients. The expression of miR-21 and -29 in peripheral blood samples of all patients was measured via the method of quantitative reverse transcription polymerase chain reaction. <P> Results: Circulating levels of miR-21 were higher in both hypertensive and HCM (p<0.001) compared to controls, while expression of miR-29 did not differ between the three studied groups. In patients with HCM and LGE-detected myocardial fibrosis in more than 4 out of 17 myocardial segments, delta CT miR-21 values were lower than in patients with myocardial LGE in 3 or fewer myocardial segments (2.71 ± 1.06 deltaCT vs. 3.50 ± 0.55 deltaCT, p<0.04), indicating the higher expression of circulating miR-21 in patients with more extensive myocardial fibrosis. <P> Conclusion: MiR-21 was overexpressed in patients with HCM and hypertensive cardiomyopathy. Importantly, in patients with HCM, more extensive myocardial fibrosis was associated with higher levels of miR-21.</P>]]></description> </item><item><title><![CDATA[Targeted Mevalonate Pathway and Autophagy in Antitumor
Immunotherapy]]></title><link>https://www.benthamscience.comarticle/137825</link><description><![CDATA[Tumors of the digestive system are currently one of the leading causes of cancer-related death worldwide. Despite considerable progress in tumor immunotherapy, the prognosis for most patients remains poor. In the tumor microenvironment (TME), tumor cells attain immune escape through immune editing and acquire immune tolerance. The mevalonate pathway and autophagy play important roles in cancer biology, antitumor immunity, and regulation of the TME. In addition, there is metabolic crosstalk between the two pathways. However, their role in promoting immune tolerance in digestive system tumors has not previously been summarized. Therefore, this review focuses on the cancer biology of the mevalonate pathway and autophagy, the regulation of the TME, metabolic crosstalk between the pathways, and the evaluation of their efficacy as targeted inhibitors in clinical tumor immunotherapy.]]></description> </item><item><title><![CDATA[Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for
Sarcoma Therapy]]></title><link>https://www.benthamscience.comarticle/137681</link><description><![CDATA[Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.]]></description> </item><item><title><![CDATA[An Updated Review on the Significance of DNA and Protein
Methyltransferases and De-methylases in Human Diseases: From
Molecular Mechanism to Novel Therapeutic Approaches]]></title><link>https://www.benthamscience.comarticle/132369</link><description><![CDATA[Epigenetic mechanisms are crucial in regulating gene expression. These mechanisms include DNA methylation and histone modifications, like methylation, acetylation, and phosphorylation. DNA methylation is associated with gene expression suppression; however, histone methylation can stimulate or repress gene expression depending on the methylation pattern of lysine or arginine residues on histones. These modifications are key factors in mediating the environmental effect on gene expression regulation. Therefore, their aberrant activity is associated with the development of various diseases. The current study aimed to review the significance of DNA and histone methyltransferases and demethylases in developing various conditions, like cardiovascular diseases, myopathies, diabetes, obesity, osteoporosis, cancer, aging, and central nervous system conditions. A better understanding of the epigenetic roles in developing diseases can pave the way for developing novel therapeutic approaches for affected patients.]]></description> </item><item><title><![CDATA[Current Status of Hedgehog Signaling Inhibitors]]></title><link>https://www.benthamscience.comarticle/137369</link><description><![CDATA[The Hedgehog (Hh) signaling pathway plays a crucial role in diverse biological processes such as cell differentiation, proliferation, senescence, tumorigenesis, malignant transformation, and drug resistance. Aberrant Hh signaling, resulting from mutations and excessive activation, can contribute to the development of various diseases during different stages of biogenesis and development. Moreover, it has been linked to unfavorable outcomes in several human cancers, including basal cell carcinoma (BCC), multiple myeloma (MM), melanoma, and breast cancer. Hence, the presence of mutations and excessive activation of the Hh pathway presents obstacles and constraints in the realm of cancer treatment. Extant research has demonstrated that small molecule inhibitors are regarded as the most effective therapeutic approaches for targeting the Hh pathway in contrast to traditional chemotherapy and radiotherapy. Consequently, this review focuses on the present repertoire of small molecule inhibitors that target various components of the Hh pathway, including Hh ligands, Ptch receptors, Smo transmembrane proteins, and Gli nuclear transcription factors. This study provides a comprehensive analysis of small molecules' structural and functional aspects in the preclinical and clinical management of cancer. Additionally, it elucidates the obstacles encountered in targeting the Hh pathway for human cancer therapy and proposes potential therapeutic approaches.]]></description> </item><item><title><![CDATA[Deciphering Potential Role of Hippo Signaling Pathway in Breast Cancer: A
Comprehensive Review]]></title><link>https://www.benthamscience.comarticle/136774</link><description><![CDATA[Breast cancer is a heterogeneous disease and a leading malignancy around the world. It is a vital cause of untimely mortality among women. Drug resistance is the major challenge for effective cancer therapeutics. In contrast, cancer stem cells (CSCs) are one of the reasons for drug resistance, tumor progression, and metastasis. The small population of CSCs present in each tumor has the ability of self-renewal, differentiation, and tumorigenicity. CSCs are often identified and enriched using a variety of cell surface markers (CD44, CD24, CD133, ABCG2, CD49f, LGR5, SSEA-3, CD70) that exert their functions by different regulatory networks, i.e., Notch, Wnt/β-catenin, hedgehog (Hh), and Hippo signaling pathways. Particularly the Hippo signaling pathway is the emerging and very less explored cancer stem cell pathway. Here, in this review, the Hippo signaling molecules are elaborated with respect to their ability of stemness as epigenetic modulators and how these molecules can be targeted for better cancer treatment and to overcome drug resistance.]]></description> </item><item><title><![CDATA[Kaempferol: A Dietary Flavonol in Alleviating Obesity]]></title><link>https://www.benthamscience.comarticle/133012</link><description><![CDATA[Obesity is considered as a chronic and high-prevalence disease on a global scale which affects all genders and ages. Although various drugs have been confirmed for the treatment of obesity, these medications have been shown to have a number of adverse effects on health. It is highlighted that natural products have an alleviative role in a broad spectrum of diseases, in particular obesity, and diabetes. Kaempferol (KMP), a plant- derived flavonol, is considerably engaged in the suppression of oxidative stress, radical scavenging, opposing cellular toxicity, and induction of the production and release of growth factors. This flavonol combats obesity by suppressing adipogenesis, regulating lipid and glucose metabolism, changing gut microbiota, and activating autophagy. Also, studies have shown that KMP exerts its anti-obesity actions by decreasing the accumulation of lipids and triglycerides (TGs), increasing fatty acid oxidation, and regulating multiple metabolic genes in the adipocytes. Considering that KMP may be a potential candidate for combating obesity, this paper summarizes the possible therapeutic roles of KMP in the treatment and prevention of this disease.]]></description> </item><item><title><![CDATA[Caveolae’s Behavior in Norm and Pathology]]></title><link>https://www.benthamscience.comarticle/131585</link><description><![CDATA[<p>Objectives: Caveolins are universal multifunctional physiologically active microparticles that collaborate in the caveolae formation to maintain the metabolic homeostatic balance of the cells. In fact, remarkable advances in the molecular biopathology of caveolae have been made in recent years by exploring the role of caveolae in norm and physiopathology. <p> Methods: The current literature data on the caveolae behavior in norm and pathology were revised. <p> Results: Caveolae are expressed in various cell types, highly concentrated in endothelial cells, cardiomyocytes, and epithelial cells. Physiologically, caveolae contribute to maintaining a signaling balance between the various homeostatic processes, including pro-growth and pro-survival, such as endothelial nitric oxide synthase, glycogen synthase kinase-3&#946;, p42/p44 mitogen-activated protein kinase, PKA, SFK, PKC, Akt through regulation of tyrosine kinases, G protein-coupled receptor, endothelial nitric oxide synthase, and MAPK pathways, and their signaling dysfunction is directly attributed to the pathogenesis of cardiovascular diseases, regeneration inhibition, neurodegenerative diseases, infection, osteoporosis, diabetes, and tumour induction and progression. <p> Conclusion: Regulation of the ratio and penetrance of caveolae activity/expression is a clinically significant potential therapeutic strategy to enhance the current therapies and eliminate the etiopathogenetic pathway of rising homeostatic disorders.</p>]]></description> </item><item><title><![CDATA[Significance of Beta-Blocker in Patients with Hypertensive Left Ventricular
Hypertrophy and Myocardial Ischemia]]></title><link>https://www.benthamscience.comarticle/129214</link><description><![CDATA[<p> Background: Arterial Hypertension (HTN) is a key risk factor for left ventricular hypertrophy (LVH) and a cause of ischemic heart disease (IHD). The association between myocardial ischemia and HTN LVH is strong because myocardial ischemia can occur in HTN LVH even in the absence of significant stenoses of epicardial coronary arteries. </p><p> Objective: To analyze pathophysiological characteristics/co-morbidities precipitating myocardial ischemia in patients with HTN LVH and provide a rationale for recommending beta-blockers (BBs) to prevent/treat ischemia in LVH. </p><p> Methods: We searched PubMed, SCOPUS, PubMed, Elsevier, Springer Verlag, and Google Scholar for review articles and guidelines on hypertension from 01/01/2000 until 01/05/2022. The search was limited to publications written in English. </p><p> Results: HTN LVH worsens ischemia in coronary artery disease (CAD) patients. Even without obstructive CAD, several pathophysiological mechanisms in HTN LVH can lead to myocardial ischemia. In the same guidelines that recommend BBs for patients with HTN and CAD, we could not find a single recommendation for BBs in patients with HTN LVH but without proven CAD. There are several reasons for the proposal of using some BBs to control ischemia in patients with HTN and LVH (even in the absence of obstructive CAD). </p><p> Conclusion: Some BBs ought to be considered to prevent/treat ischemia in patients with HTN LVH (even in the absence of obstructive CAD). Furthermore, LVH and ischemic events are important causes of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death; these events are another reason for recommending certain BBs for HTN LVH.</p>]]></description> </item><item><title><![CDATA[Labelling Matrix Metalloproteinases]]></title><link>https://www.benthamscience.comarticle/128845</link><description><![CDATA[Matrix metalloproteinases (MMPs) are a family of zinc-containing proteases that participate in many physiological and pathological processes in vivo. Recently, the MMP network has been established according to a deeper understanding of its functions. Some MMPs have been also regarded as biomarkers of various diseases, including inflammation, nerve diseases, and cancers. MMP labelling has been thus paid more attention in recent decades. Accordingly, both reagents and technologies for MMP labelling have been rapidly developed. Here we summarize the recent development of some MMP labelling methods. This review was identified through keyword (MMPs; labelling; etc.) searches in the ScienceDirect database, Scifinder, Web of Science, and PubMed for which typical cases were used for an inductive overview. In spite of the advances in MMP labelling, selective labelling of a specific MMP is still an open issue. We hope that this article can be helpful in developing specific MMP labelling methods in future.]]></description> </item><item><title><![CDATA[Combating Childhood Cancer: Paediatric Patients Living with Neuroblastoma
- Regulatory Ramifications and Roadblocks]]></title><link>https://www.benthamscience.comarticle/128114</link><description><![CDATA[This paper relates to Neuroblastoma (NBL), a rare, solid cancer affecting children and aims to describe regulatory obligations to adhere to during development, marketing authorisation application (MAA) and post-authorisation stage. The focus is on European Union (EU) paediatric legislation, although essential US Food and Drug Administration (FDA) elements are briefly outlined. Practical regulatory aspects and reporting requirements, players in the therapeutic area as well as clinical management are described. The feasibility and limitations of future harmonised clinical development are pointed out.]]></description> </item><item><title><![CDATA[Molecular Mechanisms of miR-214 Involved in Cancer and Drug
Resistance]]></title><link>https://www.benthamscience.comarticle/123009</link><description><![CDATA[As a transcriptional regulation element, the microRNA plays a crucial role in many aspects of molecular biological processes, like cellular metabolism, cell division, cell death, cell movement, intracellular signaling, and immunity. Previous studies suggested that microRNA-214 (miR-214) is probably a valuable cancer marker. In this study, a brief updated overview of the vital dual role of miR-214 in cancer as a tumor suppressor or oncogene was provided. We also examined target genes and signaling pathways related to the dysregulation of miR-214 reported in previous experimental research on various human diseases. To highlight the critical function of miR-214 in the prognostic, diagnostic, and pathogenesis of cancer diseases, we focused on the probable clinical biomarker and drug resistance function of miR-214. The current research provides a comprehensive perspective of the regulatory mechanisms governed by miR-214 in human disease pathogenesis and a list of probable candidates for future study.]]></description> </item><item><title><![CDATA[Multi-targeted HDAC Inhibitors as Anticancer Agents: Current
Status and Future Prospective]]></title><link>https://www.benthamscience.comarticle/126518</link><description><![CDATA[Multi-targeted agents can interact with multiple targets sequentially, resulting in synergistic and more effective therapies for several complicated disorders, including cancer, even with relatively modest activity. Histone deacetylase (HDAC) inhibitors are low molecular weight small compounds that increase the acetylation of histone and nonhistone proteins, altering gene expression and thereby impacting angiogenesis, metastasis, and apoptosis, among other processes. The HDAC inhibitors affect multiple cellular pathways thus producing adverse issues, causing therapeutic resistance, and they have poor pharmacokinetic properties. The designing of HDAC-based dual/multi-target inhibitor is an important strategy to overcome adverse effects, drug resistance and increase the effectiveness in controlling cancer. The selection of target combinations to design multitarget HDAC inhibitor is generally accomplished on the basis of systematic highthroughput screening (HTS), network pharmacology analysis methods. The identification of the pharmacophore against individual targets is performed using rational or computation methods. The identified pharmacophore can combine with merged, fused, or linked with the cleavable or non-cleavable linker to retain the interaction with the original target while being compatible with the other target. The objective of this review is to elucidate the potential targets' design strategies, biological activity, and the recent development of dual/multi-targeting HDAC inhibitors as potential anticancer agents. This review elucidates the designing strategies of the potential target along with biological activity and the recent development of dual/multi-targeting HDAC inhibitors as potential anticancer agents. The development of HDAC-based dual/multi-target inhibitors is important for overcoming side effects, drug resistance, and effective cancer control.]]></description> </item><item><title><![CDATA[Involvement of Metabolites and Non-coding RNAs in Diseases]]></title><link>https://www.benthamscience.comarticle/126461</link><description><![CDATA[Non-coding RNAs have a role in gene regulation and cellular metabolism control. Metabolism produces metabolites which are small molecules formed during the metabolic process. So far, a direct relationship between metabolites and genes is not fully established; however, pseudogenes and their progenitor genes regulate health and disease states. Other non-coding RNAs also contribute to this regulation at different cellular processes. Accumulation and depletion of metabolites accompany the dynamic equilibrium of health and disease state. In this study, metabolites, their roles in the cell, and the link between metabolites and non-coding RNAs are discussed.]]></description> </item><item><title><![CDATA[Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for
Cancer Therapy]]></title><link>https://www.benthamscience.comarticle/125887</link><description><![CDATA[Inhibition of histone deacetylases (HDACs) has proven to be an effective strategy for cancer therapy. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. An agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDACi. Representative classes of reported hybrid HDACis are reviewed here to shed light on the design of novel hybrid HDACis for cancer therapy.]]></description> </item><item><title><![CDATA[Perillaldehyde Building Block’s Derivatives: Targeted Bioactivities and
Molecular Docking]]></title><link>https://www.benthamscience.comarticle/123450</link><description><![CDATA[<p>Background: Recently, the essential oil (EO) of Ammodaucus leucotrichus has attracted particular attention in hemi-synthesis due to the reactivity of its main monoterpenes. <p> Objective: In vitro cytotoxic and antileishmanial activities of the EO and hemi-synthesized compounds were evaluated, and an in-silico simulation was conducted. <p> Methods: The EO was characterized by GC-MS. Two benzodiazepines (C1, C2), benzimidazole (C3), and Schiff base (C4) were hemi-synthesized by an in situ condensation of its major monoterpenes (perillaldehyde) with different amine derivatives. Synthesized compounds and the EO were evaluated for their cytotoxic activity against laryngeal carcinoma-Hep2 and rhabdomyosarcoma-RD cell lines and for their antileishmanial activity against Leishmania (L) major. Molecular docking was performed to pin the binding interactions of active molecules. <p> Results: A significant cytotoxic effect of benzodiazepines C1 and C2 was noted against Hep2 cells (IC<sub>50</sub>/C1 = 39.48 ±0.7 μM, IC<sub>50</sub>/C2 = 48.82±1.33 μM) and RD (IC<sub>50</sub>/C1 = 15.96±1.99 μM; IC50/C2 = 74.3±2.44 μM), while the EO highly inhibited Hep2 cell lines (IC<sub>50</sub>/EO = 17.3±0.85 μg/mL). C4 strongly inhibited L. major growth with an IC<sub>50</sub> value of 8.00±1.37 Μμ. The docking scores of ligand-C4 on L. major pteridine reductase and L. major methionyl-tRNA synthetase and ligands-(C1, C2) on the human protein kinase and epidermal growth factor kinase presented significant affinity to the receptor active sites (&#916;G from -7.7 to -8.8 kcal/mol). <p> Conclusion: The cytotoxic effect of derivatives C1, C2, and EO, as well as the anti-parasitic effect of C4, may suggest them as effective bioactive agents or pharmaceutical probes.</p>]]></description> </item><item><title><![CDATA[<i>Hoslundia opposita</i> Vahl. - A Promising Source of Bioactive Compounds
against Infectious and Non-infectious Diseases]]></title><link>https://www.benthamscience.comarticle/126483</link><description><![CDATA[Hoslundia opposita is an aromatic plant of the family Lamiaceae and the only member of the Hoslundia genus. It is used traditionally for treating HIV/AIDs related diseases, Breast cancer, gonorrhea, syphilis, appendicitis, epilepsy and convulsion, malaria, etc. A review of relevant literature on biology, folkloric uses, phytochemistry and pharmacology were done. The electronic databases searched included Google Scholar, PubMed, Science Direct, Wiley and Springer. Sixteen bioactive compounds have been isolated from the plants, namely; 3-O-benzoylhosloppone, 3-Ocinnamoylhosloppone, 3-O-benzoylhinokiol, 3-O-benzoylhosloquine, Euscaphic acid, 5,7- dimethoxy6-methylflavone, Hoslunddiol, Oppositin, 5-O-methylhoslundin, Tectochrysin, Hoslundin, Hoslunfuranine, 5-O-methylhoslunfuranine, Hosloppin, Hoslundal and Ursolic acid. The plant, with its phytochemicals, has shown various pharmacological effects such as antimalarial, antidiabetes, antioxidant, anti-inflammatory, anticancer and immunomodulatory effects. This review presented scientific findings on the therapeutic potential of Hoslundia opposita against several infectious and non-infectious diseases. There is a need for further investigation of the mechanism underlying the therapeutic potential of this plant against various diseases. There is also a need for clinical trials which will validate its efficacy and safety.]]></description> </item><item><title><![CDATA[Computational Model for Prediction of Foxo Protein Employing Ensemble
Learning Algorithm]]></title><link>https://www.benthamscience.comarticle/124007</link><description><![CDATA[<p>Aims: In this paper, Forkhead box O (FOXO) protein using the ensemble learning algorithm is predicted. When FOXO is in excess in the human body, it leads to LNCap prostate cancer cells, and if deficit leading neurodegenerative diseases. <p> Objective: Neurodegenerative diseases, like Alzheimer's and Parkinson's, are neurological illnesses that are caused by damaged brain cells. For prediction of FOXO protein, Gradient Boosted Machine (GBM) and Random forest (RF) techniques are used. <p> Method: The main idea of using GBM is its non-linear nature but it is difficult for any single decision tree to fit all training. To overcome this, an RF algorithm is used. RF combines the results at the end of the process by average or majority rules, while the GBM algorithm combines the results along the way. <p> Results: A total of 29.16% improvement has been observed by RF over GBM. Average square error is also evaluated to check the testing and training of data for 100 trees on 100 tree sizes. <p> Conclusion: In this paper, a computational model for the prediction of FOXO protein using ensemble learning techniques (Random Forest and GBM) has been proposed. If the dataset has many variable features and the prediction accuracy is not as important then RF can be considered. On the other hand, GBMs are better suited for datasets that have very few or fewer input features and where high accuracy predictions are required. However, there are instances when either GBM or RF can perform equally well depending on how they are tuned.</p>]]></description> </item><item><title><![CDATA[Perspectives on Epigenetic Markers in Adaptation to Physical Exercise]]></title><link>https://www.benthamscience.comarticle/121694</link><description><![CDATA[]]></description> </item><item><title><![CDATA[The Role of NF-&#954;B in Myocardial Ischemia/Reperfusion Injury]]></title><link>https://www.benthamscience.comarticle/125515</link><description><![CDATA[Acute myocardial infarction (AMI) is a threat to human life and physical health worldwide. Timely reperfusion is very important to limit infarct size and protect ischemic myocardium. Unfortunately, it has also caused severer myocardial damage, which is called “myocardial ischemia/ reperfusion injury (MIRI)”. There is no effective clinical treatment for it. Over the past two decades, biological studies of NF-&#954;B have improved the understanding of MIRI. Nuclear Factor-&#954;B (NF-&#954;B) is a major transcription factor associated with cardiovascular health and disease. It is involved in the release of pro-inflammatory factors and apoptosis of cardiomyocytes. Recent studies have shown that inhibition of NF-&#954;B plays a protective role in acute hypoxia and reperfusion injury. Here we review the molecular regulation of NF-&#954;B in MIRI, better understanding of NF-&#954;B signaling mechanisms related to inflammation and crosstalk with endogenous small molecules. We hope this review will aid in improving therapeutic approaches to clinical diagnosing. This review provides evidence for the role of NF-&#954;B in MIRI and supports its use as a therapeutic target.]]></description> </item><item><title><![CDATA[Ethnopharmacology and Biological Activities of <i>Aristolochia longa</i>: A Review]]></title><link>https://www.benthamscience.comarticle/121391</link><description><![CDATA[Aristolochia longa is a plant belonging to the genus Aristolochia, family Aristolochiaceae, whose rhizomes represent the most important part used in the pharmaceutical field mainly due to its richness in bioactive molecules. Several investigations have shown numerous biological properties, including antibacterial, antifungal, anti-inflammatory, antioxidant, and anti-cancer activities. Besides, many chemical components such as alkaloids, glycosides, phenolic compounds, tannins, flavonoids, terpenoids, and saponins have been isolated, and their structures have been elucidated. However, Aristolochia longa is still not investigated. Therefore, more studies should be conducted to discover other biological activities of Aristolochia longa, as well as those of other species from the same genus, and identify compounds responsible for these activities.]]></description> </item><item><title><![CDATA[Osthole: Synthesis, Structural Modifications, and Biological Properties]]></title><link>https://www.benthamscience.comarticle/120853</link><description><![CDATA[Osthole, a naturally occurring coumarin-type compound, is isolated from the Chinese herbal medicine Cnidium monnieri (L.) and exhibits a broad range of biological properties. In this review, the total synthesis and structural modifications of osthole and its analogs are described. Additionally, the progress on bioactivities of osthole and its analogs has been outlined since 2016. Moreover, the structure-activity relationships and mechanisms of action of osthole and its derivatives are discussed. These can provide references for future design, development, and application of osthole and its analogs as drugs or pesticides in the fields of medicine and agriculture.]]></description> </item><item><title><![CDATA[ITGA9: Potential Biomarkers and Therapeutic Targets in Different Tumors]]></title><link>https://www.benthamscience.comarticle/123126</link><description><![CDATA[Integrins are a class of cell surface adhesion molecules composed of α subunit (ITGA) and β subunit (ITGB). They belong to heterodimer transmembrane glycoproteins. Their main function in organisms is as the receptor of cell adhesion molecules (CAMs) and extracellular matrix (ECM). According to the current research integration analysis, integrin α9 (ITGA9) is one of the integrin subunits, and there are few studies on ITGA9 among integrins. ITGA9 can improve cell migration and regulate various cellular biological functions, such as tumor cell proliferation, adhesion, invasion, and angiogenesis. However, its abnormal expression mechanism in cancer and its specific role in tumor growth and metastasis are still unknown to a great extent. This review reveals the role of ITGA9 in the complex pathogenesis of many tumors and cancers, providing a new direction for the treatment of tumors and cancers. Relevant studies were retrieved and collected through the PubMed system. After determining ITGA9 as the research object, we found a close relationship between ITGA9 and tumorigenesis by analyzing the research articles on ITGA9 in the PubMed system in the last 15 years and further determined the references mainly based on the influencing factors of the articles. Thus, the role of ITGA9 in tumor and cancer genesis, proliferation, and metastasis was reviewed and analyzed. ITGA9 is an integrin subunit, which has been proved to be abnormally expressed in many tumors. After sorting and analyzing the research data, it was found that the abnormal expression of ITGA9 in a variety of tumors, including glioblastoma, rhabdomyosarcoma, melanoma, hepatocellular carcinoma, nasopharyngeal carcinoma, multiple myeloma, non-small cell lung cancer, and prostate cancer, was closely related to the proliferation, metastasis, adhesion, and angiogenesis of tumor cells. These results suggest that ITGA9 plays an important role in the occurrence and development of tumors. The integrin subunit ITGA9 may serve as a biomarker for the diagnosis of tumors and a potential therapeutic target for anti-tumor therapies.]]></description> </item><item><title><![CDATA[Tumor-related Molecular Regulatory Mechanisms of Long Non-coding
RNA RMST: Recent Evidence]]></title><link>https://www.benthamscience.comarticle/119214</link><description><![CDATA[<P>Background: Long non-coding RNA rhabdomyosarcoma 2-associated transcript (LncRNA RMST) can affect every aspect of tumor progressions, such as proliferation, translocation, and apoptosis. As a result, RMST can be used as an attractive biomarker for early diagnosis and clinical therapies of different disease states. This article aims to review pathophysiological functions, molecular mechanisms as well as promising biotherapies of RMST in multiple tumors. <P> Methods: Through the systematic induction and summary of 46 papers published in PubMed concerning this study, the molecular mechanisms of RMST in all kinds of tumors have been reviewed. <P> Results: LncRNA RMST is a tumor-related regulatory mediator, aberrantly expressed in diverse tumors, including medullary thyroid cancer, hepatocellular carcinoma, endometrial carcinoma, colon cancer, pancreatic cancer, glioma, Wilm’s tumor, and breast cancer. Furthermore, as a mechanismbased player, RMST probably guides the translation and post-translation modification, containing DNA methylation and SUMOylation. It is capable of regulating distinct tumor cells and stem cells of biological behaviors via various molecular pathways. <P> Conclusion: LncRNA RMST, potentially as an original therapeutic target, is valuable in the occurrence, development, and apoptosis of different tumors.</P>]]></description> </item><item><title><![CDATA[Genitourinary Tract Tumors in Children: An Update]]></title><link>https://www.benthamscience.comarticle/120106</link><description><![CDATA[<p>Background: Genitourinary tract tumors in children are less common than in adults. Most of these tumors have different genetic backgrounds, clinical presentation, and oncologic behavior than their adult counterpart. As a result of low prevalence in children, some of the treatment approaches and recommendations are based on treatment experience in adult patients. However, thanks to scientific and technological development, survival rates have risen considerably. <p> Objective: This paper presents a review of the principal features of the tumors involving the genitourinary tract in children and an update in genetic background, diagnosis, and treatment. <p> Methods: A narrative review was performed on published literature about genitourinary tract tumors in pediatric patients. Papers presented in English and Spanish literature were reviewed. PubMed, Science Direct, and SciELO databases were used to collect information and present this article. <p> Results: Kidney tumors are the most common type of genitourinary tumors in children. Among those, Wilms tumor represents the majority of cases and shows the successful work of clinical trial groups studying this tumor type. Other tumors involving the genitourinary tract in children include Rhabdomyosarcoma, Transitional cell carcinoma, Testicular, and Adrenal tumors. <p> Conclusion: Genitourinary tract tumors in children represent significant morbidity and economic burden, so awareness in early diagnosis represents improvement in treatment, clinical, and oncological outcomes.</p>]]></description> </item><item><title><![CDATA[<i>In-vitro</i> and <i>In-vivo</i> Experimental Models for MERS-CoV, SARSCoV,
and SARS-CoV-2 Viral Infection: A Compendious Review]]></title><link>https://www.benthamscience.comarticle/120348</link><description><![CDATA[SARS-CoV-2 belongs to the Coronaviridae family of coronaviruses. This novel virus has predominantly affected a vast world population and was declared a pandemic outbreak. The clinical and scientific communities strive to develop and validate potential treatments and therapeutic measures. The comparative study of existing synthetic drugs, evaluation of safety aspects, and the devel opment of novel vaccines can be efficiently achieved by using suitable animal models of primary infection and validating translational findings in human cell lines and tissues. The current paper explores varied animal and cell/tissue models employed and recapitulate various critical issues of ailment manifestation in humans to develop and evaluate novel therapeutic countermeasures and even include some novel patent developed in this regard.]]></description> </item><item><title><![CDATA[Privileged Scaffolds Targeting Bromodomain-containing Protein 4]]></title><link>https://www.benthamscience.comarticle/120774</link><description><![CDATA[In recent years, bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra terminal domain (BET) family, has been one of the most widely studied targets. BRD4 is a transcriptional regulation factor, which regulates cell transcription, marks mammalian biological mitosis, regulates cell cycle, and plays an important role in the biological process of cancer occurrence and development. It has been demonstrated that the imbalance or dysfunction of BRD4 expression leads to various types of cancers, including testicular gene nuclear protein melanoma, acute myeloid leukemia, colon cancer, breast cancer, liver cancer, and midline cancer. Therefore, inhibition of BRD4 has become a valuable approach in the treatment of these cancers. To date, there are numerous BRD4 inhibitors in preclinical development, some of which have entered human clinical trials. In this review, current progress in the development of privileged scaffolds designed as BRD4 inhibitors will be discussed by focusing on structure-activity relationship, selectivity, and mechanisms of action.]]></description> </item><item><title><![CDATA[A Case of Giant Cervical Polyp]]></title><link>https://www.benthamscience.comarticle/116980</link><description><![CDATA[<p>Introduction: Cervical polyps are small pedunculate, often sessile neoplasm of the cervix. It is not known whether this is due to chronic inflammation, or abnormal local responsiveness to hormonal stimulation, or localized vascular congestion of cervical blood vessels. They occur most frequently in multiparous women in the fifth decade of life. <p> Case Description: Here, we are reporting a case of a giant cervical polyp in a 38-year-old nulliparous lady who reported heavy menstrual bleeding and mass per vagina. <p> Conclusion: Since a giant cervical polyp can mimic chronic inversion of the uterus, cervical fibroid, endometrial polyp, and cervical malignancy, it requires ruling out of these conditions before GnRH therapy.</p>]]></description> </item><item><title><![CDATA[Targeting Ferroptosis Pathways: A Novel Strategy for Cancer Therapy]]></title><link>https://www.benthamscience.comarticle/120829</link><description><![CDATA[Ferroptosis is an iron-dependent nonapoptotic kind of regulated cell death resulting from the destruction of redox balance in the cytosol. Unlike apoptosis, ferroptosis is caused by an increase in intracellular iron and lipid peroxides that causes significant damage to the membrane lipid bilayer and mitochondria leading to cell death. Increased iron level in the cell promotes ROS production. Ferroptosis inducer molecules increase ROS production and inhibit the antioxidant defence mechanism to facilitate ferroptosis in cancer cells. Inhibition of GPX4, redox-active iron availability, and lipid peroxidation are major contributors to ferroptosis. Ferroptosis is involved in many diseases like heart disease, neurodegenerative disease, and cancer. Ferroptosis induction recently emerged as an attractive strategy for cancer therapy. In this review, we discuss the regulatory mechanism of ferroptosis, its different hallmarks, including genetic and metabolic regulators and inducers that promote ferroptosis in the cancer cells. Finally, the latest progress and development in ferroptosis research in different cancers focusing on proposing a novel strategy in cancer therapy are discussed.]]></description> </item><item><title><![CDATA[Dimeric Drugs]]></title><link>https://www.benthamscience.comarticle/117239</link><description><![CDATA[This review intends to summarize the structures of an extensive number of symmetrical-dimeric drugs, having two monomers, linked via a bridging entity emphasizing the versatility of biologically active substances reported to possess dimeric structures. The major number of these compounds consists of anticancer agents, antibiotics/ antimicrobials, and anti-AIDS drugs. Other symmetrical-dimeric drugs include antidiabetics, antidepressants, analgesics, anti-inflammatories, drugs for the treatment of Alzheimer’s disease, anticholesterolemics, estrogenics, antioxidants, enzyme inhibitors, anti- Parkinsonians, laxatives, antiallergy compounds, cannabinoids, etc. Most of the articles reviewed do not compare the activity/potency of the dimers to that of their corresponding monomers. Only in limited cases, various suggestions have been made to justify the unexpectedly higher activity of the dimers vs. that of the corresponding monomers. These suggestions include statistical effects, the presence of dimeric receptors, binding of a dimer to two receptors simultaneously, and others. It is virtually impossible to predict which dimers will be preferable to their respective monomers, or which linking bridges will lead to the most active compounds. It is expected that the extensive variety of substances mentioned, and the assortment of their biological activities should be of interest to academic and industrial medicinal chemists.]]></description> </item><item><title><![CDATA[Computed Tomography (CT) Features of Pelvic Rhabdomyosarcoma
(RMS) in Children]]></title><link>https://www.benthamscience.comarticle/117506</link><description><![CDATA[Background: Currently, there are few literature reports on the CT features of pelvic rhabdomyosarcoma, most of which exist in the form of case reports, and some literature reports have suggested that CT features of pelvic rhabdomyosarcoma lack specificity. This study was designed to investigate the CT features of pelvic RMS in children to provide imaging evidence for clinical diagnosis. <p> Methods: We retrospectively reviewed radiographic and clinical data of all paediatric patients with pelvic neoplastic lesions pathologically proven to be malignant in our hospitals from January 2012 through March 2021. The data of the included paediatric patients were divided into two groups according to whether the pathology results indicated RMS. CT features of RMS (<i>n</i> = 37) and non- RMS (<i>n</i> = 91) were compared by two abdominal radiologists. <p> Results: A total of 9 CT features were statistically significant for the diagnosis of pelvic RMS in children (<i>p</i> < 0.05). The sensitivity (range, 0.64-0.74) and specificity (range, 0.86-0.93) of the CT features showing multinodular fusion, surrounding blood vessels, and heterogeneous progressive centripetal enhancement were both relatively high. The CT features indicating lower than muscle density, necrosis, non-calcification and non-haemorrhage exhibited high specificity (range, 0.86-0.97), but the sensitivity (range, 0.32-0.40) was relatively low, while the sensitivity (range, 0.37-0.46) and specificity (range, 0.75-0.83) of other CT features used for diagnosing pelvic RMS, namely, lobulated and lymphatic metastasis, were both relatively low. <p> Conclusion: Pelvic rhabdomyosarcoma in children has its own specific CT features.]]></description> </item><item><title><![CDATA[Radioprotective Effects of Plants from the Lamiaceae Family]]></title><link>https://www.benthamscience.comarticle/111012</link><description><![CDATA[Background: Edible and medicinal plants are still an interesting source of promising biologically active substances for drug discovery and development. At a time of increasing cancer incidence in the world, alleviating the bothersome side effects of radiotherapy in debilitated cancer patients is becoming an important challenge. <p> Objective: The aim of the study was to overview the literature data concerning the radioprotective activity of extracts, essential oils, and some chemical compounds obtained from 12 species belonging to the Lamiaceae family, gathering of numerous spice and medicinal plants rich in valuable phytochemicals. <p> Results: The analysis of available publications showed radioprotective effectiveness of essential oils and complex extracts containing phenolic acids and flavonoids in various <i>in vitro</i> and <i>in vivo</i> models. Relatively welldocumented preventive properties exhibited the following species: <i>Mentha × piperita, Ocimum tenuiflorum, Origanum vulgare</i>, and <i>Rosmarinus officinalis</i>. However, few plants such as <i>Lavandula angustifolia, Mentha arvensis, M. spicata, Plectranthus amboinicus, Salvia miltiorrhiza, S. officinalis, Scutellaria baicalensis</i>, and <i>Zataria multiflora</i> should be more investigated in the future. Among the mechanisms of radioprotective effects of well-studied extracts and phytochemicals, it can be mentioned mainly the protection against chromosomal damage, scavenging free radicals, decreasing of lipid peroxidation and elevating of glutathione, superoxide dismutase, catalase, and alkaline phosphatase enzyme levels as well as the reduction of the cell death. The plant substances protected the gastrointestinal tract, bone marrow and lung fibroblasts. <p> Conclusion: The studied species of Lamiaceae family and their active chemical compounds are potent in alleviating the side effects of radiotherapy and should be considered as a complementary therapy.]]></description> </item><item><title><![CDATA[NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation
Inhibitors in Treatment of Inflammatory Diseases and
Cancer]]></title><link>https://www.benthamscience.comarticle/113393</link><description><![CDATA[Mitochondrial dysfunction and oxidative stress are prominent features of a plethora of human disorders. Dysregulation of mitochondrial functions represents a common pathogenic mechanism of diseases such as neurodegenerative disorders and cancer. The maintenance of the Nicotinamide adenine dinucleotide (NAD+) pool, and a positive NAD+/NADH ratio, are essential for mitochondrial and cell functions. The synthesis and degradation of NAD+ and transport of its key intermediates among cell compartments play an important role in maintaining optimal NAD levels, for the regulation of NAD+-utilizing enzymes, such as sirtuins (Sirt), poly-ADP-ribose polymerases, and CD38/157 enzymes, either intracellularly as well as extracellularly. In this review, we present and discuss the links between NAD+, NAD+-consuming enzymes, mitochondria functions, and diseases. Attempts to treat various diseases with supplementation of NAD+ cycling intermediates and inhibitors of sirtuins and ADP-ribosyl transferases may highlight a possible therapeutic approach for therapy of cancer and neurodegenerative diseases.]]></description> </item><item><title><![CDATA[The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents]]></title><link>https://www.benthamscience.comarticle/112532</link><description><![CDATA[Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders&#039; pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.]]></description> </item><item><title><![CDATA[Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research]]></title><link>https://www.benthamscience.comarticle/118953</link><description><![CDATA[<P>Background: Intrinsic rhythms in host and cancer cells play an imperative role in tumorigenesis and anticancer therapy. Circadian medicine in cancer is principally reliant on the control of growth and development of cancer cells or tissues by targeting the molecular clock and implementing time-of-day-based anticancer treatments for therapeutic improvements. In recent years, based on extensive high-throughput studies, we witnessed the arrival of several drugs and drug-like compounds that can modulate circadian timekeeping for therapeutic gain in cancer management. <P> Objective: This perspective article intends to illustrate the current trends in circadian medicine in cancer, focusing on clock-modulating pharmacological compounds and circadian regulation of anticancer drug metabolism and efficacy. <P> Scope and Approach: Considering the critical roles of the circadian clock in metabolism, cell signaling, and apoptosis, chronopharmacology research is exceedingly enlightening for understanding cancer biology and improving anticancer therapeutics. In addition to reviewing the relevant literature, we investigated the rhythmic expression of molecular targets for many anticancer drugs frequently used to treat different cancer types. <P> Key Findings and Conclusion: There are adequate empirical pieces of evidence supporting circadian regulation of drug metabolism, transport, and detoxification. Administration of anticancer drugs at specific dosing times can improve their effectiveness and reduce the toxic effects. Moreover, pharmacological modulators of the circadian clock could be used for targeted anticancer therapeutics such as boosting circadian rhythms in the host can markedly reduce the growth and viability of tumors. All in all, precision chronomedicine can offer multiple advantages over conventional anticancer therapy.</P>]]></description> </item><item><title><![CDATA[Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib]]></title><link>https://www.benthamscience.comarticle/115535</link><description><![CDATA[<P>Background: Most children with recurrent metastatic solid tumors have high mortality rates. Recent studies have shown that proteasome inhibition leads to effective tumor killing in cells that have acquired treatment resistance and metastatic properties. </P><P> Objective: The purpose of this study was to test the potential of Carfilzomib (CFZ), a proteasome inhibitor, in refractory pediatric solid tumors which is currently unknown. </P><P> Methods: A panel of pediatric solid tumor cell lines, including neuroblastoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma and atypical teratoid rhabdoid tumor (ATRT), was used to evaluate the cytotoxic and proteasomal inhibitory effects of CFZ. A drug scheduling experiment was performed to determine the optimal dose and time to obtain effective cell killing. Combination studies of CFZ with chemotherapeutic drugs of different classes were performed to determine the extent of synergy. </P><P> Results: CFZ showed effective cytotoxicity against all cell lines tested (mean IC50 = 7nM, range = 1-20nM) and activity in a fluorophore-tagged cell-based proteasome assay. Drug scheduling experiments showed that the minimum exposure of 4-8 hours/day is needed for effective cumulative killing. CFZ, when combined with chemotherapeutic drugs of different classes, synergistically enhanced the extent of cell death. </P><P> Conclusion: CFZ showed cytotoxic activity against all the solid pediatric cancer cell lines tested. This study provides initial in vitro data on the potential of CFZ to treat pediatric solid tumors and supports further investigations into the components of drug scheduling, biological correlates and drug combinations for future early phase clinical trials in children.</P>]]></description> </item><item><title><![CDATA[Characterizing the Relationship Between the Chemical Structures of Drugs and their Activities on Primary Cultures of Pediatric Solid Tumors]]></title><link>https://www.benthamscience.comarticle/115387</link><description><![CDATA[<P>Background: Despite continued efforts to develop new treatments, there is an urgent need to discover new drug leads to treat tumors exhibiting primary or secondary resistance to existing drugs. Cell cultures derived from patient-derived orthotopic xenografts are promising pre-clinical models to better predict drug response in cancer recurrence. </P><P> Objective: The aim of the study was to investigate the relationship between the physiochemical properties of drugs and their in vitro potency as well as identifying chemical scaffolds biasedtowards selectivity or promiscuity of such drugs. </P><P> Methods: The bioactivities of 158 drugs screened against cell cultures derived from 30 cancer orthotopic patient-derived xenograft (O-PDX) models were considered. Drugs were represented by physicochemical descriptors and chemical structure fingerprints. Supervised learning was employed to model the relationship between features and in vitro potency. </P><P> Results: Drugs with in vitro potency for alveolar rhabdomyosarcoma and osteosarcoma tend to have a higher number of rings, two carbon-hetero bonds and halogens. Selective and promiscuous scaffolds for these phenotypic targets were identified. Highly-predictive models of in vitro potency were obtained across these 30 targets, which can be applied to unseen molecules via a webserver (https://rnewbie.shinyapps.io/Shobek-master). </P><P> Conclusion: It is possible to identify privileged chemical scaffolds and predict the in vitro potency of unseen molecules across these 30 targets This information and models should be helpful to select which molecules to screen against these primary cultures of pediatric solid tumors.</P>]]></description> </item><item><title><![CDATA[An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking]]></title><link>https://www.benthamscience.comarticle/117083</link><description><![CDATA[<P>Background: GLI proteins play a significant role in the transduction of the Hedgehog (Hh) signaling pathway. A variety of human cancers, including the brain, gastrointestinal, lung, breast, and prostate cancers, demonstrate inappropriate activation of this pathway. GLI helps in proliferation and has an inhibitory role in the differentiation of hematopoietic stem cells. Malignancies may have a defect in differentiation. Different types of malignancies and undifferentiated cells have a low level of HLA expression on their cell surface. </P><P> Objective: Human Leukocytic Antigen (HLA) downregulation is frequently observed in cancer cells. This work is aimed to hypothesize whether this downregulation of HLA molecules is GLI oncoprotein mediated or not. To understand the roles of different types of GLI oncoproteins on different classes of HLA transcriptional machinery was carried out through structure-based modeling and molecular docking studies. </P><P> Methods: To investigate the role of GLI in HLA expression /downregulation is Hh-GLI mediated or not, molecular docking based computational interaction studies were performed between different GLI proteins (GLI1, GLI2, and GLI3) with TATA box binding protein (TBP) and compare the binding efficiencies of different HLA gene (both HLA class I and –II) regulating transcription factors (RelA, RFX5, RFXAP, RFXANK, CIITA, CREB1, and their combinations) with TBP. Due to unavailability of 3D protein structures of GLI2 and cyclin D2 (a natural ligand of GLI1) were modelled followed by structural validation by Ramachandran plot analysis. </P><P> Results: GLI proteins especially, GLI1 and GLI2, have almost similar binding energy of RFX5-RFXANK- RFXAP and CIITA multi-protein complex to TBP but has lower binding energy between RelA to TBP. </P><P> Conclusion: This study suggests that HLA class I may not be downregulated by GLI; however, over-expression of GLI1 is may be responsible for HLA class II downregulation. Thus this protein may be responsible for the maintenance of the undifferentiated state of malignant cells. This study also suggests the implicative role of GLI1 in the early definitive stage of hematopoiesis.</P>]]></description> </item><item><title><![CDATA[Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury]]></title><link>https://www.benthamscience.comarticle/117516</link><description><![CDATA[<P>Background: ALMS1-IT1, a recently identified lncRNA, has been proven to play a crucial role in regulating tumor progression and predicting the survival time of tumor patients. Data analysis from the Human Body Map (HBM) revealed that ALMS1-IT1 is expressed mainly in brain tissues. </P><P> Methods: In this study, the role of ALMS1-IT in regulating neuro-inflammation and functional recovery was investigated after ischemic cerebral damage. To this end, the rat model of transient middle cerebral artery occlusion (tMCAO) was constructed, the cell model of oxygen-glucose deprivation (OGD) was established using BV2 microglial cells, and the aberrant expression of ALMS1-IT1 was assessed in brain tissues. After ALMS1- IT1 knockdown through intrathecal injection of Lv-shALMS1-IT1, neuro-inflammatory response and functional tests including a modified neurological severity score (mNSS) and a foot-fault test were assessed. </P><P> Results: The level of ALMS1-IT1 was promptly enhanced at 12 hours (h) following MCAO, peaking at 48 h, and remaining high at day 14 compared to the sham group. Pro-inflammatory cytokines (IL-1&#946;, IL-6, and TNF- &#945;) were increased after MCAO, whereas ALMS1-IT1 inhibition suppressed the expression of IL-1&#946;, IL-6 and TNF-&#945; in MCAO rats. The results from mNSS and foot-fault test showed that ALMS1-IT1 knockdown significantly improved spatial learning and sensorimotor function of MCAO rats. Mechanistically, ALMS1-IT1 knockdown suppressed the activation of NF-&#954;B signaling in vitro and in vivo, as evidenced by decreased p65 expression and p65 nuclear translocation. ALMS1-IT1 overexpression facilitated pro-inflammatory cytokines expression in microglia, whereas the effect was blocked by treatment with JSH-23 (a specific NF-&#954;B inhibitor). </P><P> Conclusion: These data demonstrated that ALMS1-IT1 inhibition improved neurological function of MCAO rats, at least in part by repressing NF-&#954;B-dependent neuro-inflammation.</P>]]></description> </item><item><title><![CDATA[Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts]]></title><link>https://www.benthamscience.comarticle/112679</link><description><![CDATA[The tumor microenvironment is a dynamic ecosystem where malignant cells interact with the stromal cells sustaining and promoting tumor growth and metastasis. Cancer-associated fibroblasts (CAFs) are the major component of tumor stroma. CAFs control key tumorigenic activities by participating in immune evasion and suppression, extracellular matrix remodeling, neo-angiogenesis, and drug resistance. Therefore, targeting CAFs emerges as an attractive anti-cancer strategy. This review summarized recent advancements in targeting CAFs with diagnostic and therapeutic radiopharmaceuticals using clinically-promising biomarkers. The efforts to improve clinical outcomes via the application of new radiotheranostic compounds are discussed in the context of radionuclide, the pharmacophore, and, more generally, in terms of biomarker specificity and expression across different cancers and CAF phenotypes.]]></description> </item><item><title><![CDATA[Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure]]></title><link>https://www.benthamscience.comarticle/115016</link><description><![CDATA[<p>Aims: Non-invasive indices to evaluate left ventricular changes during ischemic heart failure are needed to quantify the myocardial impairment and the effectiveness of therapeutic manoeuvres. The aims of this work were to calculate the Wall Thickening Fraction (WTF) and the Augmentation Index (AIx) and to assess the relationship between WTF and AIx using data obtained from an animal model with heart failure followed by a myocardial ischemia stage and a reperfusion stage. </P><P> Methods: Nine Corriedale sheep that had been monitored for 10 minutes during a basal stage underwent 5-minute myocardial ischemia, followed by 60-minute reperfusion. Seven of them were subjected to an induced heart failure through an overdose of halothane, two of which were treated with intra-aortic counterpulsation during the reperfusion stage. The remaining two animals were monitored during their ischemia-reperfusion stage. </P><P> Results: Data obtained in the 5 animals suffering from heart failure followed by myocardial ischemia showed that: a) heart failure induction determined decrease in cardiac output, cardiac index and systolic and diastolic aortic pressure (AoP) with respect to their basal values (p<0.05), b) myocardial ischemia decreased the WTF compared with basal and induced heart failure values (p<0.05), c) during the reperfusion stage accompanied by induced heart failure, WTF increased with respect to values observed during the ischemia induction stage (p<0.05); nevertheless, basal values were not recovered after reperfusion (p<0.05). During this 60-minute stage, systolic and diastolic AoP values were lower (p<0.05) than those at the basal stage. </P><P> Conclusion: AIx and WTF values calculated from synchronically recorded values of aortic pressure and left ventricular wall thickness during the reperfusion stage in all animals (n = 9) showed a negative correlation (p<0.05). Analysed data provided evidence of a negative relationship between a left ventricular index of myocardial function and an arterial index obtained from AoP waves.</p>]]></description> </item><item><title><![CDATA[Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells]]></title><link>https://www.benthamscience.comarticle/108693</link><description><![CDATA[<p>Background: Valproic acid (VPA) is an HDAC inhibitor (HDACI) with an anticancer activity, but is hepatotoxic. N-(2-hydroxyphenyl)-2-propylpentanamide (o-OH-VPA) is a VPA aryl derivative designed in silico as a selective inhibitor of HDAC8 with biological properties against HeLa, rhabdomyosarcoma and breast cancer cell cultures. </P><P> Objective: We studied the epigenetic mechanism of o-OH-VPA as an HDACI and evaluated whether it was toxic to normal cells. </P><P> Methods: HeLa cells and primary human fibroblasts were used for this study as carcinogenic and normal cells, respectively. Cell survival was evaluated by MTT assay, whereas viability and doubling time were determined by the Trypan-blue method. HDAC activity was tested using the colorimetric HDAC activity assay. The expression of p21 was analyzed by PCR and HDAC8 expression was also evaluated by real-time PCR. Cell cycle and caspase-3 activity were analyzed by flow cytometry and caspase-3 colorimetric assay, respectively. </P><P> Results: o-OH-VPA (IC<sub>50</sub> = 0.1 mM) was fifty-eight times more effective than VPA (IC<sub>50</sub> = 5.8 mM) to reduce HeLa cell survival. Furthermore, o-OH-VPA increased the doubling time of HeLa cells by 33% with respect to the control. o-OH-VPA acted as HDACI in HeLa cells without affecting the HDAC8 expression, arresting the cell cycle of HeLa cells in the G0/G1 phase due to the increase in p21 expression with the inhibition of caspase-3 activity without exhibiting toxicity toward normal cells. </P><P> Conclusion: Our results revealed that o-OH-VPA is an HDACI with a selective effect against HeLa cells but without the known toxicity exerted by most pan-HDACIs on normal cells.</p>]]></description> </item><item><title><![CDATA[The Role of Mechanical Regulation in Cartilage Tissue Engineering]]></title><link>https://www.benthamscience.comarticle/114723</link><description><![CDATA[Due to the lack of vascular distribution and the slow metabolism, cartilage tissue cannot repair itself, which remains a huge challenge in cartilage regeneration. Tissue engineering using stem cells appears to be a promising method for cartilage repair. Tissue engineers demonstrated that mechanical stimulation can enhance the quality of engineered cartilage, making it more similar to natural cartilage in structure and function. In this review, we summarize recent studies on the role of mechanical stimuli in chondrogenesis, focusing on the applications of extrinsic mechanical loading and the studies on mechanical properties of biomaterials in cartilage tissue engineering. This review will provide fresh insights into the potential use of mechanical stimuli for clinical use.]]></description> </item><item><title><![CDATA[Reposition of the Fungicide Ciclopirox for Cancer Treatment]]></title><link>https://www.benthamscience.comarticle/114109</link><description><![CDATA[<P>Background: Ciclopirox (CPX), a broad-spectrum fungicide, has been widely used to treat fungal infection on the skin and nails for decades. Recent preclinical and clinical studies have shown that CPX also possesses promising anticancer activity. </P><P> Objective: The objective of this study is to summarize the patents, the pharmacological and toxicological properties, the anticancer activity, and the mechanisms of action of CPX and its derivatives as anticancer agents. </P><P> Methods: PubMed and Google using the keywords “ciclopirox”, “cancer or tumor” and “patent” were searched, and the identified literature was reviewed. </P><P> Results: Pharmacological and toxicological profiles from preclinical and clinical studies support that systemic administration of CPX and its derivatives is feasible and safe for cancer treatment. CPX exerts its anticancer activity by inhibiting cell proliferation, inducing apoptosis, suppressing cell migration and invasion, and inhibiting angiogenesis and lymphangiogenesis. Mechanistically, CPX impacts the expression or activities of multiple signaling molecules or pathways, such as ribonucleotide reductase, Myc, DJ-1, Wnt/&#946;-catenin, DOHH/eIF5A/PEAK1, VEGFR-3/ERK1/2, ATR/Chk1/Cdc25A, and AMPK/TSC/mTORC1. Most of these effects are attributed to iron chelation by CPX. Five patents have been retrieved: four patents on the development of CPX prodrugs to improve the water solubility and bioavailability of CPX, and one patent on the methods of bladder cancer treatment with CPX, CPX-O, or a CPX prodrug. </P><P> Conclusion: CPX has a great potential to be repositioned for cancer therapy.</P>]]></description> </item><item><title><![CDATA[Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review]]></title><link>https://www.benthamscience.comarticle/112768</link><description><![CDATA[Cancer is a genetic disease triggered by gene mutations, which control cell growth and their functionality inherited from previous generations. The targeted therapy of some tumors was not especially successful. A host of new techniques can be used to treat aptamer-mediated targeting, cancer immunotherapy, cancer stem cell (CSC) therapy, cell-penetrating peptides (CPPs), hormone therapy, intracellular cancer cell targeting, nanoparticles, and viral therapy. These include chemical-analog conjugation, gene delivery, ligand-receptor-based targeting, prodrug therapies, and triggered release strategies. Virotherapy is a biotechnological technique for turning viruses into therapeutic agents by the reprogramming of viruses to cure diseases. In several tumors, including melanoma, multiple myeloma, bladder cancer, and breast cancer, the oncolytic capacity of oncolytic Coxsackievirus has been studied. The present study aims to assess oncolytic Coxsackievirus and its mechanisms of effect on cancer cells.]]></description> </item><item><title><![CDATA[Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment]]></title><link>https://www.benthamscience.comarticle/113936</link><description><![CDATA[Hepatocellular carcinoma (HCC) is one of the most common solid tumours and the second leading cause of cancer-related mortality worldwide. Advanced-recurrent HCC often requires a systemic drug therapy where multi tyrosine kinase inhibitor, Sorafenib represents the first-line therapy option. But it exhibited very limited survival benefit and tumour response due to the early emergence of drug resistance and drug-related adverse effect. Immunotherapy approaches now being widely studied as an effective alternative treatment for HCC. Several immune checkpoint inhibitors (ICI), such as Nivolumab and Pembrolizumab, are approved as monotherapy in sorafenib-resistant HCC patients. But, the existence of a plethora of immunosuppressive signals in the tumour microenvironment often leads to unsuccessful immunotherapies. In this context, combinatorial immunotherapies are getting much acceptance as a way to improve therapeutic outcomes by blocking immunosuppressive signals in the tumour microenvironment (TME). The combination of Vascular Endothelial Growth Factor (VEGF) inhibitors with ICI resulted in significant synergistic effects in various preclinical and clinical studies. However, the adverse effects associated with current synthetic VEGF inhibitors limit its clinical utility. In this review, we have summarized the potential of phytochemicals, especially the category of flavonoids, alkaloids, glycosides, terpenoids, and coumarin, as the available-affordable-safe-effective repositories of VEGF inhibitors. Their possibilities as an alternative for synthetic VEGF inhibitors by synergistic combination with ICI are reviewed, thereby enhancing patient compliance and survival rates. This review highlights the demand for a detailed investigation of the plausible role of plant-based anti-angiogenic-immunotherapy combination against HCC.]]></description> </item><item><title><![CDATA[Natural Products as Anticancer Agents]]></title><link>https://www.benthamscience.comarticle/112855</link><description><![CDATA[Medicinal plants and mushrooms have always fascinated the world as an attractive source of natural compounds for cancer therapy. From ancient times, they have been valued as gourmet food and folk medicine in Oriental practice. For over 40 years, the world has witnessed the overwhelming interest of the western scientific fraternity in the pharmaceutical potential of natural products in combating cancer. The plants and mushrooms credited with success against angiogenesis and cancer metastasis belong to certain Plants, including Catharanthus roseus, Aloe Vera,Annona muricata,Curcuma longa, Withania somnifera, and Berberis and mushrooms such as Agaricus, Antrodia, Ganoderma, Grifolafrondosa, Hericiumerinaceus, Phellinuslinteus, and Trametesversicolor Coriolusversicolor. The anti-cancer compounds play a pivotal role as a free radical scavenger and reactive oxygen species inducer, mitotic spindle kinase inhibitor, anti-mitotic, angiogenesis inhibitor, topoisomerase inhibitor, apoptosis inducers, and eventually checking cancer invasion, migration and proliferation. The present review updates and focuses on the recent findings of the pharmacologically potential bioactive compounds, their anti-tumor potential, and underlying mechanism of preventing cancer metastasis and angiogenesis in order to raise knowledge for further investigations to develop cancer therapeutics with no adverse side effects The mounting experimental evidence at pre-clinical and clinical levels from various research groups across the globe, regarding prevention of cancer metastasis by natural products unarguably make it a fast-track research area worth mass attention.]]></description> </item><item><title><![CDATA[Anti-Tumor Activity and Underlying Mechanism of Phomoxanthone B in MCF7 Cells]]></title><link>https://www.benthamscience.comarticle/111809</link><description><![CDATA[<p>Background: Xanthones are a class of heterocyclic natural products, which are promising sources of anti-cancer leads. Phomoxanthone B (PXB) and Phomoxanthone A(PXA)are xanthone dimers. PXA is wellstudied as an anti-cancer agent, but PXB is not. In our study, PXB was isolated from the endophytic fungus Phomopsis sp. By254. </P><P> Objective: The purpose of this study was to identify the underlying anti-tumor mechanisms of PXB in breast cancer MCF7 cell line. </P><P> Methods: Apoptosis, cell cycle, proliferation, invasion, and migration assays were used to assess the anti-tumor activity of PXB. RNA sequencing was used to analyze the effect of PXB treatment on gene expression in MCF7 cells. </P><P> Results: PXB showed cytotoxicity towards a variety of tumor cells, especially MCF7 cells. PXB inhibited the migration and invasion, arrested cell cycle at G2/M phase, and induced apoptosis associated with caspase-3 activation in MCF7 cells. The detailed transcriptome analysis revealed that PXB affected several pathways related to tumorigenesis, metabolisms, and oxidative phosphorylation in MCF7 cells. KEGG transcriptome analysis revealed that PXB upregulated pro-survival signal pathways, such as MAPK, PI3K-AKT, and STAT3 pathways. We found that PXB also significantly upregulated the expression of IL24, DDIT3, and XAF1, which may contribute to PXB-induced apoptosis. We further found that PXB may downregulate oxidative phosphorylation by decreasing the expression of electron transport chain genes, especially MT-ND1, which is a potential unfavorable prognostic marker for ER-positive breast cancer. </P><P> Conclusion: PXB exerts strong cytotoxicity against human tumor cells and has a potential for ER-positive breast cancer treatment.</p>]]></description> </item><item><title><![CDATA[Ewing Sarcoma Family Tumors: Past, Present and Future Prospects]]></title><link>https://www.benthamscience.comarticle/111848</link><description><![CDATA[<p>Ewing’s sarcoma (ES), also known as mesenchymal primitive neuroectodermal tumor (PNET), is a malignant round blue cell tumor (MRBCT) with a varying degree of neuronal differentiation. PNET arises from the primitive nerve cells of the central nervous system (CNS) but may also occur in the bones of the extremities, pelvis, vertebral column, and chest wall. Extraskeletal ES/PNET may affect the various soft tissues, including those of the pelvis, paraspinal region, and thoracopulmonary region. </P><P> Histopathological differentiation between ES, PNET, and other related sarcomas is often difficult. On light microscopy, the same histopathological appearance of ES has been termed PNET, Askin- Rosay (A-R) tumor, and malignant neuroepithelioma by various other authors. The immunohistochemical distinction is also difficult due to poor tissue differentiation and low intake of the various specific immunohistochemical markers. The most frequent translocation is t (11; 22) (q24; q12), resulting in the EWSR1-FLI1 fusion gene detected in nearly 90% of cases and is considered the hallmark of the diagnosis of ES, PNET, atypical ES, and A-R tumor. Therefore, ES, atypical ES, PNET, and A-R tumor are currently regarded as one entity grouped together under the Ewing Family Tumor (EFT) and are treated in an identical way. EFT represents only about 3% of all pediatric malignancies. The annual incidence is between 2 and 5 cases per million children per year. The peak prevalence of the tumor is between the ages of 10 and 15 years. The incidence is higher in males than in females, with a ratio of 1.3:1. </P><P> Newer groups of MRBCT that have great similarities to EFT are being recently described. These tumors, atypical EFT and Ewing’s like Sarcomas (ELS), bear similarities to EFT but have basic morphological and molecular differences. Optimal treatment requires the use of adjuvant and new-adjuvant chemotherapy (CTR), radical surgical resection and/or involves field radiotherapy (RT). The reported disease-free survival (DFS) and overall survival (OS) range between 45-80% and 36-71%, respectively. The overall prognosis for the metastatic and recurrent disease remains poor. The use of newer conventional and targeted medications, improved RT delivery, and surgical techniques may further improve the outcomes. The past few years have seen advances in genomics-based sarcoma diagnosis and targeted therapies. In this comprehensive review article, we provide a detailed report of EFT and discuss the various clinical aspects and the recent advances used in the diagnosis and treatment.</p>]]></description> </item><item><title><![CDATA[Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer]]></title><link>https://www.benthamscience.comarticle/111120</link><description><![CDATA[<P>Background: Curcumin, an active compound of turmeric spice, is one of the most-studied natural compounds and has been widely recognized as a chemopreventive agent. Several molecular mechanisms have proven that curcumin and its analogs play a role in cancer prevention through modulating various cell signaling pathways as well as in the inhibition of the carcinogenesis process. </P><P> Objective: To study the potential role of curcumin in the management of various types of cancer through modulating cell signalling molecules based on available literature and recent patents. </P><P> Methods: A wide-ranging literature survey was performed based on Scopus, PubMed, PubMed Central, and Google scholar for the implication of curcumin in cancer management, along with a special emphasis on human clinical trials. Moreover, patents were searched through www.google.com/patents, www.freepatentsonline.com, and www.freshpatents.com. </P><P> Result: Recent studies based on cancer cells have proven that curcumin has potential effects against cancer cells as it prevents the growth of cancer and acts as a cancer therapeutic agent. Besides, curcumin exerted anti-cancer effects by inducing apoptosis, activating tumor suppressor genes, cell cycle arrest, inhibiting tumor angiogenesis, initiation, promotion, and progression stages of tumor. It was established that co-treatment of curcumin and anti-cancer drugs could induce apoptosis and also play a significant role in the suppression of the invasion and metastasis of cancer cells. </P><P> Conclusion: Accumulating evidences suggest that curcumin has the potential to inhibit cancer growth, induce apoptosis, and modulate various cell signaling pathway molecules. Well-designed clinical trials of curcumin based on human subjects are still needed to establish the bioavailability, mechanism of action, efficacy, and safe dose in the management of various cancers.</P>]]></description> </item><item><title><![CDATA[Focus on MicroRNAs as Biomarker in Pediatric Diseases]]></title><link>https://www.benthamscience.comarticle/110802</link><description><![CDATA[<P>Background: MiRNAs are a class of small non-coding RNAs that are involved in the post-transcriptional regulation of gene expression. MiRNAs are considered a class of epigenetic biomarkers. These biomarkers can investigate disease at different stages: diagnosis, therapy or clinical follow-up. </P><P> Objective: The aim of this paper is to highlight the innovative use of miRNAs in several childhood diseases. </P><P> Methods: We conducted a literature review to search the usage of miRNAs in pediatric clinical routine or experimental trials. </P><P> Results: We found a possible key role of miRNAs in different pediatric illnesses (metabolic alterations, coagulation defects, cancer). </P><P> Conclusion: The modest literature production denotes that further investigation is needed to assess and validate the promising role of miRNAs as non-invasive biomarkers in pediatric disorders.</P>]]></description> </item><item><title><![CDATA[Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System]]></title><link>https://www.benthamscience.comarticle/108492</link><description><![CDATA[The Glioblastoma Multiforme (GBM; grade IV astrocytoma) exhorts tumors of star-shaped glial cells in the brain. It is a fast-growing tumor that spreads to nearby brain regions specifically to cerebral hemispheres in frontal and temporal lobes. The etiology of GBM is unknown, but major risk factors are genetic disorders like neurofibromatosis and schwannomatosis, which develop the tumor in the nervous system. The management of GBM with chemo-radiotherapy leads to resistance, and current drug regimen like Temozolomide (TMZ) is less efficacious. The reasons behind the failure of drugs are due to DNA alkylation in the cell cycle by enzyme DNA guanidase and mitochondrial dysfunction. Naturally occurring bioactive compounds from plants referred as phytochemicals, serve as vital sources for anti-cancer drugs. Some prototypical examples include taxol analogs, vinca alkaloids (vincristine, vinblastine), podophyllotoxin analogs, camptothecin, curcumin, aloe-emodin, quercetin, berberine etc. These phytochemicals often regulate diverse molecular pathways, which are implicated in the growth and progression of cancers. However, the challenges posed by the presence of BBB/BBTB to restrict the passage of these phytochemicals, culminates in their low bioavailability and relative toxicity. In this review, we integrated nanotech as a novel drug delivery system to deliver phytochemicals from traditional medicine to the specific site within the brain for the management of GBM.]]></description> </item><item><title><![CDATA[Rectifying Attenuated Store-Operated Calcium Entry as a Therapeutic Approach for Alzheimer’s Disease]]></title><link>https://www.benthamscience.comarticle/113440</link><description><![CDATA[<P>Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Although the pathological hallmarks of AD have been identified, the derived therapies cannot effectively slow down or stop disease progression; hence, it is likely that other pathogenic mechanisms are involved in AD pathogenesis. Intracellular calcium (Ca<sup>2+</sup>) dyshomeostasis has been consistently observed in AD patients and numerous AD models and may emerge prior to the development of amyloid plaques and neurofibrillary tangles. Thus, intracellular Ca<sup>2+</sup> disruptions are believed to play an important role in AD development and could serve as promising therapeutic intervention targets. </P><P> One of the disrupted intracellular Ca<sup>2+</sup> signaling pathways manifested in AD is attenuated storeoperated Ca<sup>2+</sup> entry (SOCE). SOCE is an extracellular Ca<sup>2+</sup> entry mechanism mainly triggered by intracellular Ca<sup>2+</sup> store depletion. Maintaining normal SOCE function not only provides a means for the cell to replenish ER Ca<sup>2+</sup> stores but also serves as a cellular signal that maintains normal neuronal functions, including excitability, neurogenesis, neurotransmission, synaptic plasticity, and gene expression. However, normal SOCE function is diminished in AD, resulting in disrupted neuronal spine stability and synaptic plasticity and the promotion of amyloidogenesis. Mounting evidence suggests that rectifying diminished SOCE in neurons may intervene with the progression of AD. In this review, the mechanisms of SOCE disruption and the associated pathogenic impacts on AD will be discussed. We will also highlight the potential therapeutic targets or approaches that may help ameliorate SOCE deficits for AD treatment.</P>]]></description> </item><item><title><![CDATA[Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling]]></title><link>https://www.benthamscience.comarticle/110628</link><description><![CDATA[<P>Background: The fibroblast growth factor (FGF) family is comprised of 23 highly regulated monomeric proteins that regulate a plethora of developmental and pathophysiological processes, including tissue repair, wound healing, angiogenesis, and embryonic development. Binding of FGF to fibroblast growth factor receptor (FGFR), a tyrosine kinase receptor, is facilitated by a glycosaminoglycan, heparin. Activated FGFRs phosphorylate the tyrosine kinase residues that mediate induction of downstream signaling pathways, such as RAS-MAPK, PI3K-AKT, PLC&#947;, and STAT. Dysregulation of the FGF/FGFR signaling occurs frequently in cancer due to gene amplification, FGF activating mutations, chromosomal rearrangements, integration, and oncogenic fusions. Aberrant FGFR signaling also affects organogenesis, embryonic development, tissue homeostasis, and has been associated with cell proliferation, angiogenesis, cancer, and other pathophysiological changes. </P><P> Objective: This comprehensive review will discuss the biology, chemistry, and functions of FGFs, and its current applications toward wound healing, diabetes, repair and regeneration of tissues, and fatty liver diseases. In addition, specific aberrations in FGFR signaling and drugs that target FGFR and aid in mitigating various disorders, such as cancer, are also discussed in detail. </P><P> Conclusion: Inhibitors of FGFR signaling are promising drugs in the treatment of several types of cancers. The clinical benefits of FGF/FGFR targeting therapies are impeded due to the activation of other RTK signaling mechanisms or due to the mutations that abolish the drug inhibitory activity on FGFR. Thus, the development of drugs with a different mechanism of action for FGF/FGFR targeting therapies is the recent focus of several preclinical and clinical studies.</P>]]></description> </item><item><title><![CDATA[Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer’s Disease]]></title><link>https://www.benthamscience.comarticle/110366</link><description><![CDATA[In the Central Nervous System (CNS), a specific loss of focal neurons leads to mental and neurological disorders like dementia, Alzheimer’s Disease (AD), Huntington’s disease, Parkinson’s disease, etc. AD is a neurological degenerative disorder, which is progressive and irreversible in nature and is the widely recognized reason for dementia in the geriatric populace. It affects 10% of people above the age of 65 and is the fourth driving reason for death in the United States. Numerous evidence suggests that the neuronal compartment is not the only genesis of AD, but transcription factors also hold significant importance in the occurrence and advancement of the disease. It is the need of the time to find the novel molecular targets and new techniques for treating or slowing down the progression of neurological disorders, especially AD. In this article, we summarised a conceivable association between transcriptional factors and their defensive measures against neurodegeneration and AD. The mammalian forkhead transcription factors of the class O (FoxO) illustrate one of the potential objectives for the development of new methodologies against AD and other neurocognitive disorders. The presence of FoxO is easily noticeable in the “cognitive centers” of the brain, specifically in the amygdala, hippocampus, and the nucleus accumbens. FoxO proteins are the prominent and necessary factors in memory formation and cognitive functions. FoxO also assumes a pertinent role in the protection of multiple cells in the brain by controlling the involving mechanism of autophagy and apoptosis and also modulates the process of phosphorylation of the targeted protein, thus FoxO must be a putative target in the mitigation of AD. This review features the role of FoxO as an important biomarker and potential new targets for the treatment of AD.]]></description> </item><item><title><![CDATA[Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases]]></title><link>https://www.benthamscience.comarticle/110099</link><description><![CDATA[Topoisomerases are reported to resolve the topological problems of DNA during several cellular processes, such as DNA replication, transcription, recombination, and chromatin remodeling. Two types of topoisomerases (Topo I and II) accomplish their designated tasks by introducing single- or double-strand breaks within the duplex DNA molecules, and thus maintain the proper structural conditions of DNA to release the topological torsions, which is generated by unwinding of DNA to access coded information, in the course of replication, transcription, and other processes. Both the topoisomerases have been looked at as crucial targets against various types of cancers such as lung, melanoma, breast, and prostate cancers. Conceptually, targeting topoisomerases will disrupt both DNA replication and transcription, thereby leading to inhibition of cell division and consequently stopping the growth of actively dividing cancerous cells. Since the discovery of camptothecin (an alkaloid) as an inhibitor of Topo I in 1958, a number of derivatives of camptothecin were developed as potent inhibitors of Topo I. Two such derivatives of camptothecin, namely, topotecan and irinotecan, have been commonly used as US Food and Drug Administration (FDA) approved drugs against Topo I. Similarly, the first Topo II inhibitor, namely, etoposide, an analogue of podophyllotoxin, was developed in 1966 and got FDA approval as an anti-cancer drug in 1983. Subsequently, several other inhibitors of Topo II, such as doxorubicin, mitoxantrone, and teniposide, were developed. These drugs have been reported to cause accumulation of cytotoxic non-reversible DNA double-strand breaks (cleavable complex). Thus, the present review describes the anticancer potential of plant-derived secondary metabolites belonging to alkaloids, flavonoids and terpenoids directed against topoisomerases. Furthermore, in view of the recent advances made in the field of computer-aided drug design, the present review also discusses the use of computational approaches such as ADMET, molecular docking, molecular dynamics simulation and QSAR to assess and predict the safety, efficacy, potency and identification of these potent anti-cancerous therapeutic molecules.]]></description> </item><item><title><![CDATA[Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts]]></title><link>https://www.benthamscience.comarticle/108961</link><description><![CDATA[Background: This study was designed as a continuation of a complex investigation about the phytochemical composition and biological activity of chamomile, parsley, and celery extracts against A375 human melanoma and dendritic cells. </p><p> Objective: The main aim was the evaluation of the antimicrobial potential of selected extracts as well as the in vitro anticancer activity against MCF7 human breast cancer cells. </p><p> Methods: In order to complete the picture regarding the phytochemical composition, molecular fingerprint was sketched out by the help of FTIR spectroscopy. The activity of two enzymes (acetylcholinesterase and butyrylcholinesterase) after incubation with the three extracts was spectrophotometrically assessed. The antimicrobial potential was evaluated by disk diffusion method. The in vitro anticancer potential against MCF7 human breast cancer cells was appraised by MTT, LDH, wound healing, cell cycle, DAPI, Annexin-V-PI assays. </p><p> Results: The results showed variations between the investigated extracts in terms of inhibitory activity against enzymes, such as acetyl- and butyrilcholinesterase. Chamomile and parsley extracts were active only against tested Gram-positive cocci, while all tested extracts displayed antifungal effects. Among the screened samples at the highest tested concentration, namely 60μg/mL, parsley was the most active extract in terms of reducing the viability of MCF7 - human breast adenocarcinoma cell line and inducing the release of lactate dehydrogenase. On the other hand, chamomile and celery extracts manifested potent anti-migratory effects. Furthermore, celery extract was the most active in terms of total apoptotic events, while chamomile extract induced the highest necrosis rate. </p><p> Conclusion: The screened samples containing phytochemicals belonging in majority to the class of flavonoids and polyphenols can represent candidates for antimicrobial and anticancer agents.]]></description> </item><item><title><![CDATA[Phytochemicals as Potential Curative Agents against Viral Infection: A Review]]></title><link>https://www.benthamscience.comarticle/109845</link><description><![CDATA[The present pandemic erupted due to highly contagious coronavirus SARS-CoV- 2, and lack of any efficient therapy to restrain its infection and treatment, led the scientific community to re-evaluate the efficacy of commonly available phytochemicals as potential therapeutic agents. The vast pharmacological activities and medicinal significance of the plant-derived natural products against a diverse range of physiological disorders and diseases are well documented. Under the current health emergency across the world, there is an urgent requirement of repurposing of the available FDA approved drugs and natural products which could help in controlling the infections and alleviating the severity of the diseases as discovering entirely new chemical entity as a novel drug would be a protracted and costly journey. Some of the phytochemicals have already displayed potential anti-viral activity against different targets of SARS-CoV-2 virus. The present review would provide an account of the prevalent phytochemicals with antiviral activities, which would help in the development of promising drug therapy for the treatment of COVID-19 and similar such highly infectious viruses.]]></description> </item><item><title><![CDATA[The Protective of Baicalin on Myocardial Ischemia-Reperfusion Injury]]></title><link>https://www.benthamscience.comarticle/107118</link><description><![CDATA[<P>Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R). </P><P> Methods: Sprague Dawley rats&#039; heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively. </P><P> Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor. </P><P> Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.</P>]]></description> </item><item><title><![CDATA[The Advances on the Protective Effects of Ginsenosides on Myocardial Ischemia and Ischemia-Reperfusion Injury]]></title><link>https://www.benthamscience.comarticle/107461</link><description><![CDATA[Ginseng is a traditional medicine with a complex chemical composition, wide bioactivity and unique pharmacological action. Many studies have confirmed that ginsenosides are the active ingredients of ginseng, and ginsenosides have always been the focus of different researchers. With the development of modern separation and analysis technology, more than 150 kinds of ginsenosides have been isolated. The ginsenosides Rb1, Rb2, Rc, Rg1 and Re account for more than 80% of total ginsenosides, and other saponins, such as Rd, Rg3 and Rh2, which are minor constituents, accounting for only a small portion of the total amount. In recent years, ginsenosides have been found to possess strong pharmacological activities, such as antioxidation, clearing of oxygen free radicals, reducing calcium overload and anti-apoptosis. Ginsenosides play a protective role in ischemia-reperfusion injury. This paper reviews the protective effects of ginsenosides on myocardial ischemia and ischemiareperfusion injury.]]></description> </item><item><title><![CDATA[Berberine Administration in Treatment of Colitis: A Review]]></title><link>https://www.benthamscience.comarticle/107531</link><description><![CDATA[Berberine (Brb) is one of the well-known naturally occurring compounds exclusively found in Berberis vulgaris and other members of this family, such as Berberis aristata, Berberis aroatica, and Berberis aquifolium. This plant-derived natural compound has a variety of therapeutic impacts, including anti-oxidant, anti-inflammatory, anti-diabetic, and anti-tumor. Multiple studies have demonstrated that Brb has great anti-inflammatory activity and is capable of reducing the levels of proinflammatory cytokines, while it enhances the concentrations of anti-inflammatory cytokines, making it suitable for the treatment of inflammatory disorders. Colitis is an inflammatory bowel disease with chronic nature. Several factors are involved in the development of colitis and it appears that inflammation and oxidative stress are the most important ones. With respect to the anti-inflammatory and antioxidant effects of Brb, its administration seems to be beneficial in the treatment of colitis. In the present review, the protective effects of Brb in colitis treatment and its impact on molecular pathways are discussed.]]></description> </item><item><title><![CDATA[The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging]]></title><link>https://www.benthamscience.comarticle/104874</link><description><![CDATA[<P>Background: Hepatocellular carcinoma is cancer with many new cases and the highest mortality rate. Chemotherapy is the most commonly used method for the clinical treatment of hepatocellular carcinoma. Natural products have become clinically important chemotherapeutic drugs due to their great potential for pharmacological development. Many sesquiterpene lactone compounds have been proven to have antitumor effects on hepatocellular carcinoma. </P><P> Objective: Britanin is a sesquiterpene lactone compound that can be considered for the treatment of hepatocellular carcinoma. The present study aimed to investigate the antitumor effect of britanin. </P><P> Methods: BEL 7402 and HepG2 cells were used to study the cytotoxicity and antitumor effects of britanin. Preliminary studies on the nuclear factor kappa B pathway were conducted by western blot analysis. A BEL 7402-luc subcutaneous tumor model was established for the in vivo antitumor studies of britanin. In vivo bioluminescence imaging was conducted to monitor changes in tumor size. </P><P> Results: The results of the cytotoxicity analysis showed that the IC50 values for britanin in BEL 7402 and HepG2 cells were 2.702μM and 6.006μM, respectively. The results of the colony formation demonstrated that the number of cells in a colony was reduced significantly after britanin treatment. And the results of transwell migration assays showed that the migration ability of tumor cells was significantly weakened after treatment with britanin. Tumor size measurements and staining results showed that tumor size was inhibited after britanin treatment. The western blot analysis results showed the inhibition of p65 protein expression and reduced the ratio of Bcl-2/Bax after treatment. </P><P> Conclusion: A series of in vitro and in vivo experiments demonstrated that britanin had good antitumor effects and provided an option for hepatocellular carcinoma treatment.</P>]]></description> </item><item><title><![CDATA[BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK]]></title><link>https://www.benthamscience.comarticle/103382</link><description><![CDATA[<P>Background: Prostate cancer remains one of the most common and deadliest forms of cancer, generally respond well to radical prostatectomy and associated interventions, up to 30% of individuals will suffer disease relapse. Although BUB1B was found to be essential for cell growth and proliferation, even in several kinds of tumor cells, the specific importance and mechanistic role of BUB1B in prostate cancer remain unclear. </P><P> Methods: Quantitative Real-Time PCR and Western-blot were used in the detection of mRNA and protein expression. Lentivirus infection was used to overexpression or knock down the target gene. Flow cytometry analysis was performed to test protein expression and apoptosis level. Immunohistochemistry was used to identify protein expression in tissue. Statistical differences between the two groups are evaluated by two-tailed t-tests. The comparison among multiple groups is performed by one-way Analysis of Variance (ANOVA) followed by Dunnett’s posttest. The statistical significance of the Kaplan-Meier survival plot is determined by log-rank analysis. </P><P> Results: In the present report, we found BUB1B expression to be highly increased in prostate cancer tissues relative to normal controls. We further found BUB1B to be essential for efficient tumor cell proliferation, and to correlate with poorer prostate cancer patient outcomes. From a mechanistic perspective, the ability of BUB1B to regulate MELK was found to be essential for its ability to promote prostate cancer cell proliferation. </P><P> Conclusion: Altogether, our data suggest that BUB1B is up-regulated in prostate cancer, suggesting that the growth of cancer cells may depend on BUB1B-dependent regulation of MELK transcription. BUB1B may serve as a clinical prognostic factor and a druggable target for prostate cancer.</P>]]></description> </item><item><title><![CDATA[Artemia species: An Important Tool to Screen General Toxicity Samples]]></title><link>https://www.benthamscience.comarticle/105658</link><description><![CDATA[Medicinal plants are a good source of novel therapeutic drugs, due to the phytochemicals present. Artemia, commonly known as brine shrimp, is a tiny halophilic invertebrate belonging to class Crustacean, which plays an important role in saline aquatic and marine eco-systems. Besides its usage in aquaculture, it is also highly valued for its application in toxicity detection and it is used in areas such as Ecology, Physiology, Ecotoxicology, Aquaculture and Genetics. Furthermore, Artemia based lethality assay (brine shrimp lethality assay, BSLA) is rapid, convenient and low cost. Presently, brine shrimp lethality assays are enormously employed in research and applied toxicology. It has been used in the study of natural products as a preliminary toxicity assay to screen a large number of extracts and compounds for drug discovery in medicinal plants. The aim of this review paper is to collect, organize, select and discuss the existing knowledge about the different uses of Artemia salina as a bench-top bioassay for the discovery and purification of bioactive natural products.]]></description> </item><item><title><![CDATA[Malignant Mesothelioma of the Tunica Vaginalis Testis: A Rare Malignant Tumor without Asbestos Exposure]]></title><link>https://www.benthamscience.comarticle/104889</link><description><![CDATA[Malignant mesothelioma of the tunica vaginalis testis is an extremely rare and often a deadly tumor. Preoperative diagnosis is very difficult due to the lack of specific clinical manifestations, mainly including hydrocele formation and painless inguinal mass. In this abstract, we presented a case of a young patient with hydrocele and dull pain of left testes, who was planned for laparoscopic repair of left inguinal hernia, during which a mass attached to the scrotal cord was discovered. Dissection and release of the mass from the cord structure were performed, and postoperative pathological examination revealed malignant mesothelioma arising from the left tunica vaginalis testis. The case was then referred to an oncology center where intraperitoneal hyperthermic chemotherapy with cytoreductive surgery was performed.]]></description> </item><item><title><![CDATA[B7-H3-targeted Radioimmunotherapy of Human Cancer]]></title><link>https://www.benthamscience.comarticle/96941</link><description><![CDATA[<P>Background: Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human malignancies express B7-H3 on the tumor cell surface, while expression on the majority of normal tissues is limited, presenting B7-H3 as a candidate target for RIT. This review provides an overview of the general principles of targeted RIT and discusses publications that have used radiolabeled B7-H3-targeted antibodies for RIT of cancer in preclinical or clinical studies. </P><P> Methods: Databases including PubMed, Scopus, and Google Scholar were searched for publications through June 2018 using a combination of terms including “B7-H3”, “radioimmunotherapy”, “targeted”, “radiotherapy”, and “cancer”. After screening search results for relevancy, ten publications were included for discussion. </P><P> Results: B7-H3-targeted RIT studies to date range from antibody development and assessment of novel Radioimmunoconjugates (RICs) in animal models of human cancer to phase II/III trials in humans. The majority of clinical studies have used B7-H3-targeted RICs for intra- compartment RIT of central nervous system malignancies. The results of these studies have indicated high tolerability and favorable efficacy outcomes, supporting further assessment of B7-H3-targeted RIT in larger trials. Preclinical B7-H3-targeted RIT studies have also shown encouraging therapeutic outcomes in a variety of solid malignancies. </P><P> Conclusion: B7-H3-targeted RIT studies over the last 15 years have demonstrated feasibility for clinical development and support future assessment in a broader array of human malignancies. Future directions worthy of exploration include strategies that combine B7-H3- targeted RIT with chemotherapy or immunotherapy.</P>]]></description> </item><item><title><![CDATA[Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy]]></title><link>https://www.benthamscience.comarticle/104505</link><description><![CDATA[<P>Background: Recently we developed a scalable scheme of synthesis of melphalan ester conjugate with 1,2-dioleoyl-<i>sn</i>-glycerol (MlphDG) and a protocol for the fabrication of its lyophilized liposomal formulation. </P><P> Objective: Herein we compared this new convenient in use formulation of MlphDG with parent drug Alkeran<i>®</i> in rats concerning several toxicological parameters and evaluated its antitumor efficacy in the model of breast cancer in mice. </P><P> Method: Liposomes of approximately 100 nm in diameter, consisting of egg phosphatidylcholine, soybean phosphatidylinositol, and MlphDG, or placebo liposomes without the drug were produced by extrusion and lyophilized. Alkeran<i>®</i> or liposomes recovered by the addition of water were injected into the tail vein of animals. Clinical examination of rats consisted of detailed inspection of the behavior, general status, and hematological parameters. Mice with transplanted breast cancer WNT-1 were subjected to multiple treatments with the drugs; tumor growth inhibition was assessed, together with cellular immunity parameters. </P><P> Results: Liposomes showed approximately two times lower acute toxicity and better tolerability than Alkeran<i>®</i> in terms of behavioral criteria. The toxic effects of liposomes on hemopoiesis were manifested at higher doses than in the case of Alkeran<i>®</i>, proportionally to the difference in LD50 values. The formulation inhibited tumor growth significantly more effectively than Alkeran<i>®</i>, delaying the start of the exponential growth phase and exhibiting no additional toxic effects toward bone marrow. </P><P> Conclusion: Lower toxicity of the liposomal formulation of MlphDG promises improved quality of life for cancer patients in need of treatment with melphalan. Presumably, the list of indications for melphalan therapy could be extended.</P>]]></description> </item><item><title><![CDATA[Idronoxil as an Anticancer Agent: Activity and Mechanisms]]></title><link>https://www.benthamscience.comarticle/103419</link><description><![CDATA[Idronoxil has been the subject of more than 50 peer-reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies. Whilst clinically tested in the past, idronoxil’s journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored. Here, we summarize the current literature regarding the key cellular targets of idronoxil and the mechanisms by which idronoxil exerts its anticancer effects, laying a new foundation toward giving this unique molecule a second chance of contributing to the future of cancer treatment.]]></description> </item><item><title><![CDATA[Circulating Biomarkers for Tumor Angiogenesis: Where Are We?]]></title><link>https://www.benthamscience.comarticle/92573</link><description><![CDATA[Background: In recent years, several anti-angiogenic drugs have been developed and their addition to standard treatment has been associated with clinical benefits. However, the response to anti-angiogenic therapy is characterized by considerable variability. In this context, the development of dynamic non-invasive biomarkers would be helpful to elucidate the emergence of anti-angiogenic resistance as well as to correctly address the treatment. <p></p> Objectives: The purpose of this review is to describe current reports on circulating diagnostic and prognostic biomarkers related to angiogenesis. We further discuss how this non-invasive strategy could improve the monitoring of tumor treatment and help clinical strategy. <p></p> Results: We discuss the latest evidence in the literature regarding circulating anti-angiogenic markers. Besides growth factor proteins, different circulating miRNAs could exert a pro- or anti-angiogenic activity so as to represent suitable candidates for a non-invasive strategy. Recent reports indicate that tumor-derived exosomes, which are small membrane vesicles abundant in biological fluids, also have an impact on vascular remodeling. <p></p> Conclusion: Numerous circulating biomarkers related to angiogenesis have been recently identified. Their use will allow identifying patients who are more likely to benefit from a specific anti-angiogenic treatment, as well as detecting those who will develop resistance and/or adverse effects. Nonetheless, further studies are required to elucidate the role of these biomarkers in clinical settings.]]></description> </item><item><title><![CDATA[Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research]]></title><link>https://www.benthamscience.comarticle/90777</link><description><![CDATA[Birch-bark triterpenoids and their semi-synthetic derivatives possess a wide range of biological activities including cytotoxic effects on various tumor cell lines. However, due to the low solubility and bioavailability, their medicinal applications are rather limited. The use of various nanotechnology-based drug delivery systems is a rapidly developing approach to the solubilization of insufficiently bioavailable pharmaceuticals. Herein, the drug delivery systems deemed to be applicable for birch-bark triterpenoid structures are reviewed. The aforementioned disadvantages of birch-bark triterpenoids and their semi-synthetic derivatives can be overcome through their incorporation into organic nanoparticles, which include various dendrimeric systems, as well as embedding the active compounds into polymer matrices or complexation with carbohydrate nanoparticles without covalent bonding. Some of the known triterpenoid delivery systems consist of nanoparticles featuring inorganic cores covered with carbohydrates or other polymers. Methods for delivering the title compounds through encapsulation and emulsification into lipophilic media are also suitable. Besides, the birch-bark triterpenoids can form self-assembling systems with increased bio-availability. Even more, the self-assembling systems are used as carriers for delivering other chemotherapeutic agents. Another advantage besides increased bioavailability and anticancer activity is the reduced overall systemic toxicity in most of the cases, when triterpenoids are delivered with any of the carriers.]]></description> </item><item><title><![CDATA[Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly <i>via</i> Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling]]></title><link>https://www.benthamscience.comarticle/99175</link><description><![CDATA[<P>Background: We have previously described mosaic mutations in the RNase IIIb domain of DICER1that display global developmental delays, lung cysts, somatic overgrowth, macrocephaly and Wilms tumor. This constellation of phenotypes was classified as GLOW syndrome. Due to the phenotypic overlap between GLOW and syndromes caused by mutations in the PI3K/AKT/mTOR pathway, we hypothesized that alterations in miRNA regulation of this pathway cause its specific constellation of phenotypes. </P><P> Objective: To test the hypothesis that DICER1 “hot spot” mutations associated with GLOW syndrome activate PI3K/AKT/mTOR signaling. </P><P> Methods: We developed HEK293T cells with loss of exon 25 in DICER1, a genetic modification that is synonymous with the “hot spot” RNAseIIIb mutations that cause GLOW syndrome. We assayed the cells for activation of the PI3K/AKT/mTOR signaling pathway. </P><P> Results: We observed activation of the PI3K/AKT/mTOR pathway as demonstrated by increased pS6Kinase, p4EBP1 and pTSC2 levels. Additionally, these cells demonstrate a striking cellular phenotype, with the ability to form spheres when the serum is removed from their growth medium. The cells in these spheres are Oct4 and Sox2 positive and exhibit the property of reversion with the addition of serum. We queried miRNA expression data and identified a population of miRNAs that increase due to these mutations and target negative regulators of the PI3K/AKT/mTOR pathway. </P><P> Conclusion: This work identifies the delicate and essential role for miRNA control of the PI3K/AKT/mTOR pathway. We conclude that the phenotypes observed in the GLOW syndrome are the result of PI3K/AKT/mTOR activation.</P>]]></description> </item><item><title><![CDATA[Marine Actinomycetes-derived Natural Products]]></title><link>https://www.benthamscience.comarticle/102345</link><description><![CDATA[Actinomycetes is an abundant resource for discovering a large number of lead compounds, which play an important role in microbial drug discovery. Compared to terrestrial microorganisms, marine actinomycetes have unique metabolic pathways because of their special living environment, which has the potential to produce a variety of bioactive substances. In this paper, secondary metabolites isolated from marine actinomycetes are reviewed (2013-2018), most of which exhibited cytotoxic, antibacterial, and antiviral biological activities.]]></description> </item><item><title><![CDATA[Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis]]></title><link>https://www.benthamscience.comarticle/96237</link><description><![CDATA[<P>Background: Supernumerary kidney is an accessory organ with its own encapsulated parenchyma, blood vessels and ureters, either separated from the normal kidney or connected to it via fibrous tissue and ectopic kidney is a migration abnormality of the kidney. Here, we have evaluated a rare case of the supernumerary and ectopic kidney with DMSA, MAG3 and also CT fusion of the images. </P><P> Methods: The absolute divided renal function was calculated for each kidney by DMSA. The MAG3 scintigraphy showed no obstruction in the ureteropelvic junction. Furthermore, the renogram curve and Tmax and time to ½ values were assessed. Two months after the conventional scintigraphies, the patient was referred to a CT scan and the fusion of DMSA SPECT and CT data was generated on a workstation. </P><P> Results: The ectopic supernumerary kidney was functioning very well except a small hypoactive area, visible on DMSA, which was possibly a minimal pelvicalyceal dilatation. However, consequent CT scan did not show any pathology. </P><P> Conclusion: It is important to evaluate particularly complicated or rare cases with multimodality systems with 3D or fusion techniques for the accurate diagnosis.</P>]]></description> </item><item><title><![CDATA[Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro]]></title><link>https://www.benthamscience.comarticle/94063</link><description><![CDATA[Background: Tumors of the childhood are considered to be grave and devastating pathologies, with high mortality rates. Current therapeutic options like cytotoxic drugs and radiotherapy target both healthy and malignant cells, thus resulting in long-term neurological and intellectual sequelae and endocrinological disorders. <p></p> Objectives: In this study, we focused on the anticancer potency of crocins, the main constituents of Crocus sativus L, stigmas. Crocins were first extracted using organic solvents from the dried stigmas and then were identified using the HPLC analysis. <p></p> Materials and Methods: TE-671 cells were treated with the extract of crocins using a range of concentrations between 0.25-mg/ mL and 16 mg/mL. Viability of the cells was measured at 24h, 48h, 72h and 96h. In addition, we have examined the expression levels of the p53 gene using Real-Time Reverse Transcription PCR. <p></p> Results: Results showed that crocins exerted significant cytotoxic and anti-proliferative effects in a concentration and time - dependent-manner on TE-671 cells. Furthermore, p53 manifested similar expression pattern as the anti-proliferative effect of crocin. <p></p> Conclusion: Our data demonstrate that crocins could be a novel promising agent for the improvement of tumor treatment. <p></p>]]></description> </item><item><title><![CDATA[The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice]]></title><link>https://www.benthamscience.comarticle/99994</link><description><![CDATA[Over the last few years, we have seen constant development of molecular pathology for the care of patients with cancer. The information obtained from molecular data has transformed our thinking about the biological diversity of cancers, particularly in the field of ophthalmic oncology. It has reoriented the way in which therapeutic decisions and decisions concerning patient surveillance are made, both in the area of pediatric cancers, including rhabdomyosarcoma and retinoblastoma, and adult cancers, such as uveal melanoma and lymphomas. A better definition of the molecular classification of these cancers and of the different biological pathways involved is essential to the understanding of both the pathologist and the onco-ophthalmologist. Molecular tests based on targeted or expanded analysis of gene panels are now available. These tests can be performed with tumor tissue or biofluids (especially blood) to predict the prognosis of tumors and, above all, the benefit of targeted therapies, immunotherapy or even chemotherapy. Looking for the BAP1 mutation in uveal melanoma is essential because of the associated metastatic risk. When treating retinoblastoma, it is mandatory to assess the heritable status of RB1. Conjunctival melanoma requires investigation into the BRAF mutation in the case of a locally advanced tumor. The understanding of genomic alterations, the results of molecular tests and/or other biological tests predictive of a therapeutic response, but also of the limits of these tests with respect to the available biological resources, represents a major challenge for optimal patient management in ophthalmic oncology. In this review, we present the current state of knowledge concerning the different molecular alterations and therapeutic targets of interest in ophthalmic oncology.]]></description> </item><item><title><![CDATA[Impaired Myocardial MIF/AMPK Activation Aggravates Myocardial Ischemia Reperfusion Injury in High-Fat Diet-Induced Obesity]]></title><link>https://www.benthamscience.comarticle/97553</link><description><![CDATA[<P>Background: Obese patients are more sensitive to myocardial ischemia, which has been linked with high mortality rates. The following study investigates the effects of impaired macrophage Migration Inhibitory Factor (MIF)/AMP-Activated Protein Kinase (AMPK) activation on increased susceptibility to myocardial ischemia/reperfusion (I/R) in high-fat diet-induced obesity. </P><P> Methods: Male C57BL/6J mice were fed with a normal diet (10% kcal as fat, lean group) or a high-fat diet (60kcal as fat, obese group) for 12 consecutive weeks. To detect the MIF expression and AMPK activation in response to I/R in isolated hearts from lean and obese mice, myocardial samples were collected from left ventricular areas at different time points. To determine whether MIF supplementation is protective against I/R injury, recombined MIF (10 ng/mL) was applied before ischemia. Myocardial infarct size was estimated by triphenyltetrazolium staining. Western blot was used to detect myocardial MIF expression, AMPK activation and membrane glucose transporter 4 (Glut4) expression. </P><P> Results: The expression of MIF was remarkably higher in obese group compared to lean group. Ischemia increased myocardial MIF expression and phosphorylation of AMPK in lean mice, whereas it had no significant effect on obese mice. Furthermore, administration of recombinant MIF increased ischemic AMPK activation and membrane Glut4 expression in both lean and obese mice, while it reduced the infarct size in lean mice only. </P><P> Conclusion: An impaired MIF/AMPK activation response and consequent reduced membrane Glut4 expression may play an important role in increasing myocardial susceptibility to I/R in obesity.</P>]]></description> </item><item><title><![CDATA[Achievements in Cancer Research and its Therapeutics in Hundred Years]]></title><link>https://www.benthamscience.comarticle/100018</link><description><![CDATA[Cancer research has progressed leaps and bounds over the years. This review is a brief overview of the cancer research, milestone achievements and therapeutic studies on it over the one hundred ten years which would give us an insight into how far we have come to understand and combat this fatal disease leading to millions of deaths worldwide. Modern biology has proved that cancer is a very complex disease as still we do not know precisely how it triggers. It involves several factors such as protooncogene, oncogene, kinase, tumor suppressor gene, growth factor, signalling cascade, micro RNA, immunity, environmental factors and carcinogens. However, modern technology now helps the cancer patient on the basis of acquired and established knowledge in the last hundred years to save human lives.]]></description> </item><item><title><![CDATA[STAT3: A Potential Drug Target for Tumor and Inflammation]]></title><link>https://www.benthamscience.comarticle/99122</link><description><![CDATA[STAT (Signal Transducers and Activators of Transcription) is a cellular signal transcription factor involved in the regulation of many cellular activities, such as cell differentiation, proliferation, angiogenesis in normal cells. During the study of the STAT family, STAT3 was found to be involved in many diseases, such as high expression and sustained activation of STAT3 in tumor cells, promoting tumor growth and proliferation. In the study of inflammation, it was found that it plays an important role in the anti-inflammatory and repairing of damage tissues. Because of the important role of STAT3, a large number of studies have been obtained. At the same time, after more than 20 years of development, STAT3 has also been used as a target for drug therapy. And the discovery of small molecule inhibitors also promoted the study of STAT3. Since STAT3 has been extensively studied in inflammation and tumor regulation, this review presents the current state of research on STAT3.]]></description> </item><item><title><![CDATA[Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy ]]></title><link>https://www.benthamscience.comarticle/85548</link><description><![CDATA[Chemokines, which have chemotactic abilities, are comprised of a family of small cytokines with 8-10 kilodaltons. Chemokines work in immune cells by trafficking and regulating cell proliferation, migration, activation, differentiation, and homing. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also known as CXCL12), which has been found to be expressed in more than 23 different types of cancers. Recently, the SDF-1/CXCR-4 signaling pathway has emerged as a potential therapeutic target for human tumor because of its critical role in tumor initiation and progression by activating multiple signaling pathways, such as ERK1/2, ras, p38 MAPK, PLC/ MAPK, and SAPK/ JNK, as well as regulating cancer stem cells. CXCL12/CXCR4 antagonists have been produced, which have shown encouraging results in anti-cancer activity. Here, we provide a brief overview of the CXCL12/CXCR4 axis as a molecular target for cancer treatment. We also review the potential utility of targeting CXCL12/CXCR4 axis in combination of immunotherapy and/or chemotherapy based on up-to-date literature and ongoing research progress.]]></description> </item><item><title><![CDATA[Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo]]></title><link>https://www.benthamscience.comarticle/96999</link><description><![CDATA[<P>Background: Multi Drug Resistance (MDR) is the phenomenon that cancers develop resistance to majority of chemotherapy drugs and is a serious obstacle to the treatment for Hepatocellular Carcinoma (HCC). Polo-Like Kinase 1 (PLK1) is a serine/threonine kinase associated with tumor growth and clinical prognosis in HCC and BI2536 is its potent inhibitor with IC50 of 0.83nM. </P><P> Aims: To test whether the down-regulation of PLK1 by its inhibitor BI2536 would have beneficial effects on the reversal of MDR in HCC cells. </P><P> Methods: The CCK-8 assay was used to determine the viability of HepG2/ADM and SMMC7721/ADM cells and their parental cells treated with BI2536. Then animal model studies were performed. Cell invasion assay and wound healing assay were used to determine the invasion ability and motility. Flow cytometric was used to test the apoptosis induced by BI2536. Western blot and quantitative real-time PCR were performed to test the change of expression of MDR and apoptosis-related gene. </P><P> Results: BI2536 down-regulated the expression of PLK1 protein and mRNA specifically. BI2536 can significantly reduce IC50 for ADM and other drugs in ADM-resistant HCC cells. Meanwhile, it inhibited cell viability, proliferation, and invasion, and induced cell cycle arrest and apoptosis in HCC cells with MDR. </P><P> Conclusion: Our results suggest that PLK1 inhibitor BI2536 can re-sensitize HCC cancer cell with MDR through induction of apoptosis. Thus, PLK1 inhibitor BI2536 may act as an effective chemotherapeutic drug in the clinical treatment of HCC patients with MDR.</P>]]></description> </item><item><title><![CDATA[Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends]]></title><link>https://www.benthamscience.comarticle/97704</link><description><![CDATA[Nitrogen mustards, a family of DNA alkylating agents, marked the start of cancer pharmacotherapy. While traditionally characterized by their dose-limiting toxic effects, nitrogen mustards have been the subject of intense research efforts, which have led to safer and more effective agents. Even though the alkylating prodrug mustards were first developed decades ago, active research on ways to improve their selectivity and cytotoxic efficacy is a currently active topic of research. This review addresses the historical development of the nitrogen mustards, outlining their mechanism of action, and discussing the improvements on their therapeutic profile made through rational structure modifications. A special emphasis is made on discussing the nitrogen mustard prodrug category, with Cyclophosphamide (CPA) serving as the main highlight. Selected insights on the latest developments on nitrogen mustards are then provided, limiting such information to agents that preserve the original nitrogen mustard mechanism as their primary mode of action. Additionally, future trends that might follow in the quest to optimize these invaluable chemotherapeutic medications are succinctly suggested.]]></description> </item><item><title><![CDATA[ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma]]></title><link>https://www.benthamscience.comarticle/87731</link><description><![CDATA[<P>For most cancers, the treatment of choice is still chemotherapy despite its severe adverse effects, systemic toxicity and limited efficacy due to the development of multidrug resistance (MDR). MDR leads to chemotherapy failure generally associated with a decrease in drug concentration inside cancer cells, frequently due to the overexpression of ABC transporters such as P-glycoprotein (P-gp/MDR1/ABCB1), multidrug resistance-associated proteins (MRPs/ABCCs), and breast cancer resistance protein (BCRP/ABCG2), which limits the efficacy of chemotherapeutic drugs. The aim of this review is to compile information about transcriptional and post-transcriptional regulation of ABC transporters and discuss their role in mediating MDR in cancer cells. </P><P> This review also focuses on drug resistance by ABC efflux transporters in cancer cells, particularly hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) cells. Some aspects of the chemotherapy failure and future directions to overcome this problem are also discussed.</P>]]></description> </item><item><title><![CDATA[Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications]]></title><link>https://www.benthamscience.comarticle/95747</link><description><![CDATA[Fibroblast growth factors (FGFs) are pleiotropic molecules exerting autocrine, intracrine and paracrine functions via activating four tyrosine kinase FGF receptors (FGFR), which further trigger a variety of cellular processes including angiogenesis, evasion from apoptosis, bone formation, embryogenesis, wound repair and homeostasis. Four major mechanisms including angiogenesis, inflammation, cell proliferation, and metastasis are active in FGF/FGFR-driven tumors. Furthermore, gain-of-function or loss-of-function in FGFRs1-4 which is due to amplification, fusions, mutations, and changes in tumor–stromal cells interactions, is associated with the development and progression of cancer. Although, the developed small molecule or antibodies targeting FGFR signaling offer immense potential for cancer therapy, emergence of drug resistance, activation of compensatory pathways and systemic toxicity of modulators are bottlenecks in clinical application of anti-FGFRs. In this review, we present FGF/FGFR structure and the mechanisms of its function, as well as cross-talks with other nodes and/or signaling pathways. We describe deregulation of FGF/FGFR-related mechanisms in human disease and tumor progression leading to the presentation of emerging therapeutic approaches, resistance to FGFR targeting, and clinical potentials of individual FGF family in several human cancers. Additionally, the underlying biological mechanisms of FGF/FGFR signaling, besides several attempts to develop predictive biomarkers and combination therapies for different cancers have been explored.]]></description> </item><item><title><![CDATA[Natural Cyclic Peptides as Clinical and Future Therapeutics]]></title><link>https://www.benthamscience.comarticle/95650</link><description><![CDATA[Natural cyclic peptides are conformationally constrained notable biomolecules and reveal several drug-like properties such as high binding affinity, metabolic stability, target selectivity, bioavailability, low toxicity and flexibility. They have attracted a lot of attention as alternative sources of new drugs to traditional small molecules in drug discovery. Compared to classical medicines, cyclic peptides with a novel mechanism of action are attractive for their potential therapeutic applications particularly for cancer therapy and several diseases caused by resistant and non-resistant bacteria, virus, and fungi. Herein, we provide an overview of the naturally occurring biologically active cyclic peptide therapeutic landscape, including promising candidates, which are under trial in different stages for future and/or clinically used drugs against different diseases. This will certainly be an essential resource for upcoming and existing researchers and scientists within industry and academia in medicinal, bioorganic, and natural product chemistry.]]></description> </item><item><title><![CDATA[Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment]]></title><link>https://www.benthamscience.comarticle/95833</link><description><![CDATA[Background: Purinergic signalling is involved in several physiological and pathophysiological processes. P2X7 Receptor (P2X7R) is a calcium-permeable ion channel that is gaining interest as a potential therapeutic target for the treatment of different diseases including inflammation, pain, psychiatric disorders and cancer. P2X7R is ubiquitously expressed and sensitive to high ATP levels, usually found in tumor microenvironment. P2X7R regulates several cell functions, from migration to cell death, but its selective contribution to tumor progression remains controversial. </P><P> Objective: Current review was conducted to check involvement of P2X7R use in cancer treatment. </P><P> Methods: We review the most recent patents focused on the use of P2X7R in the treatment of cancer. </P><P> Results: P2X7R is an intriguing purinergic receptor that plays different roles in tumor progression. </P><P> Conclusion: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies.]]></description> </item><item><title><![CDATA[Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review]]></title><link>https://www.benthamscience.comarticle/87462</link><description><![CDATA[Background: Lithium is a first-line treatment for bipolar disorder in adults, but its mechanism of action is still far from clear. Furthermore, evidences of its use in pediatric populations are sparse, not only for bipolar disorders, but also for other possible indications. </P><P> Objectives: To provide a synthesis of published data on the possible mechanisms of action of lithium, as well as on its use in pediatric samples, including pharmacokinetics, efficacy, and safety data. </P><P> Methods: Clinical trials in pediatric samples with at least one standardized measure of efficacy/ effectiveness were included in this review. We considered: i) randomized and open label trials, ii) combination studies iii) augmentation studies iv) case series including at least 5 patients. </P><P> Results: Different and non-alternative mechanisms of action can explain the clinical efficacy of lithium. Clinical studies in pediatric samples suggest that lithium is effective in managing manic symptoms/episodes of bipolar disorder, both in the acute phase and as maintenance strategy. Efficacy on depressive symptoms/phases of bipolar disorder is much less clear, while studies do not support its use in unipolar depression and severe mood dysregulation. Conversely, it may be effective on aggression in the context of conduct disorder. Other possible indications, with limited published evidence, are the acute attacks in Kleine-Levin syndrome, behavioral symptoms of X-fragile syndrome, and the management of clozapine- or chemotherapy- induced neutropenia. Generally, lithium resulted relatively safe. </P><P> Conclusions: Lithium seems an effective and well-tolerated medication in pediatric bipolar disorder and aggression, while further evidences are needed for other clinical indications.]]></description> </item><item><title><![CDATA[Fungal Bioactive Compounds in Pharmaceutical Research and Development]]></title><link>https://www.benthamscience.comarticle/91213</link><description><![CDATA[Background: Exploration of antibiotics from microorganisms became widespread in the academia and the industry with the serendipitous discovery of Penicillin from Penicillium notatum by Sir Alexander Fleming. This embarked the golden era of antibiotics which lasted for over 60 years. However, the traditional phenotypic screening was replaced with more rational and smarter methods of exploration of bioactive compounds from fungi and microorganisms. Fungi have been responsible for providing a variety of bioactive compounds with diverse activities which have been developed into blockbuster drugs such as Cyclosporine, Caspofungin, Lovastatin and Fingolimod etc. It has been reported that ca. 40% of the 1453 New Chemical Entities (NCE’s) approved by USFDA are natural products, natural product inspired or mimics many of which have their origins from fungi. Hence fungal compounds are playing a very important role in drug discovery and development in the pharmaceutical industry. </P><P> Methods: We undertook structured searches of bibliographic databases of peer-reviewed research literature which pertained to natural products, medicinal chemistry of natural products and drug discovery from fungi. With the strategic improvement in screening and identification methods, fungi are still a potential resource for novel chemistries. Thus the searches also comprised of bioactive agents from fungi isolated or derived from special ecological groups and lineages. To find different molecules derived or isolated from fungi under clinical studies, clinical trial data from the NIH as well as from pharmaceutical companies were also explored. This comprised of data wherein the pharmaceutical industries have acquired or licensed a fungal bioactive compound for clinical study or a trial. </P><P> Results: Natural product chemistry and medicinal chemistry continue to play an important role in converting a bioactive compound into therapeutic moieties or pharmacophores for new drug development. </P><P> Conclusion: Thus one can say fungal bioactive compounds are alive and well for development into new drugs as novel ecological groups of fungi as well as novel chemistries are being uncovered. This review further emphasizes the collaboration of fungal biologists with chemists, pharmacologists and biochemists towards the development of newer drugs for taking them into the drug development pipeline.]]></description> </item><item><title><![CDATA[Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells]]></title><link>https://www.benthamscience.comarticle/90322</link><description><![CDATA[Background: Recent reports have demonstrated the role of the G Protein-Coupled Estrogen Receptor 1 (GPER1) on the proliferation of breast cancer. The coupling of GPER1 to estrogen triggers cellular signaling pathways related to cell proliferation. </P><P> Objective: Develop new therapeutic strategies against breast cancer. </P><P> Method: We performed in silico studies to explore the binding mechanism of a set of G15 /G1 analogue compounds. We included a carboxyl group instead of the acetyl group from G1 to form amides with several moieties to increase affinity on GPER1. The designed ligands were submitted to ligand-based and structure-based virtual screening to get insights into the binding mechanism of the best designed compound and phenol red on GPER1. </P><P> Results: According to the in silico studies, the best molecule was named G1-PABA ((3aS,4R,9bR)-4-(6- bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid). It was synthesized and assayed in vitro in breast cancer (MCF-7 and MDA-MB-231) and normal (MCF-10A) cell lines. Experimental studies showed that the target compound was able to decrease cell proliferation, IC50 values of 15.93 &#181;M, 52.92 &#181;M and 32.45 &#181;M in the MCF-7, MDA-MB-231 and MCF-10A cell lines, respectively, after 72 h of treatment. The compound showed better IC50 values without phenol red, suggesting that phenol red interfere with the G1-PABA action at GPER1, as observed through in silico studies, which is present in MCF-7 cells according to PCR studies and explains the cell proliferation effects. </P><P> Conclusion: Concentration-dependent inhibition of cell proliferation occurred with G1-PABA in the assayed cell lines and could be due to its action on GPER1.]]></description> </item><item><title><![CDATA[Exosome-like Nanovesicles Isolated from Citrus limon L. Exert Antioxidative Effect]]></title><link>https://www.benthamscience.comarticle/93755</link><description><![CDATA[Background: Exosome-like nanovesicles are biological nanostructures mediating cell-tocell communication and capable to load selected cargos also in the interaction among different species. </P><P> Objective: We aimed to explore the content of exosome-like nanovesicles derived from Citrus limon L. and to analyze the effects of their uptake on human cells. </P><P> Method: We isolated exosome-like nanovesicles from Citrus limon L. juice (EXO-CLs) by differential centrifugation. EXO-CLs were analyzed for short RNA content by advanced sequencing technologies, and for ascorbic acid (vitamin C) and citrate content by enzymatic assays. EXO-CLs anti-oxidant and pro-differentiative potential was evaluated in vitro on mesenchymal stromal cells (MSC), a common tool for regenerative strategies for several human tissues. </P><P> Results: We showed that EXO-CLs carry detectable amounts of citrate and vitamin C and, although it was not possible to identify specific miRNAs, we detected short RNA sequences (20-30 bp) with unknown functions and with different distribution size in respect to whole Citrus limon L. juice. In vitro, EXO-CLs were uptaken by MSC and had a significant protective effect against oxidative stress. Furthermore, regarding the potential benefit for human bone health, we found that EXO-CLs modulate MSC differentiation versus the osteogenic lineage. </P><P> Conclusion: We demonstrated that incubation with EXO-CLs exert antioxidant activity in human cells. This is most likely due to the direct delivery and uptake of micronutrients by human cells that are well preserved inside the nanovesicle membrane, including the unstable vitamin C. Based on our results, we speculate that fruit-derived nanovesicles have the potential to mediate interspecies influence after food intake.]]></description> </item><item><title><![CDATA[Inhibitory Effect of Filipendula ulmaria on Mammary Carcinogenesis Induced by Local Administration of Methylnitrosourea to Target Organ in Rats]]></title><link>https://www.benthamscience.comarticle/89447</link><description><![CDATA[Background: The meadowsweet (Filipendula ulmaria (L.) Maxim.) may have a cancer prophylactic activity, since its extracts exhibit antioxidant, anti-inflammatory and other effects. We investigated the ability of a meadowsweet decoction to inhibit mammary carcinogenesis induced by intramammary injections of Methylnitrosourea (MNU) to the target organ in rats. </P><P> Materials and Methods: The chemical composition of meadowsweet extracts was studied by traditional methods. In animal experiments, adult outbred female rats received single injections of MNU at a dose 1mg directly into the tissue of each mammary gland. After carcinogenic exposure one group (MNU) of rats continued to receive standard feed and tap water throughout life. In another group (MNU+meadowsweet), rats were given daily a decoction of the meadowsweet instead of drinking water and standard feed. </P><P> Results: Meadowsweet extracts showed a sufficiently high content of flavonoids and tannins and also some individual phenolic compounds. In rats after injections of MNU the overall incidence of tumors was 90% with tumor multiplicity of 3.1. The majority of rats (86%) developed multiple malignant tumors of the mammary gland (most often adenocarcinomas). In rats from the group MNU+meadowsweet, there was a statistically significant decrease of the overall tumor multiplicity-by 1.5 times, and the incidence and multiplicity of breast tumors-by 1.6 and 2.2 times, respectively. </P><P> Conclusions: Meadowsweet extract can be considered an effective inhibitor of breast carcinogenesis.]]></description> </item><item><title><![CDATA[Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals]]></title><link>https://www.benthamscience.comarticle/93125</link><description><![CDATA[Currently, the most important cause of death is cancer. To treat the cancer there are a number of drugs existing in the market but no drug is found to be completely safe and effective. The toxicity of the drugs is the key problem in the cancer chemotherapy. However, plants and plant derived bioactive molecule have proved safe and effective in the treatment of cancers. Phytochemicals that are found in fruits, vegetables, herbs, and plant extract have been usually used for treating cancer. It has been established that several herbal drug have a strong anticancer activity. However, their poor bioavailability, solubility, and stability have severely restricted their use. These problems can be overcome by incorporating the herbal drug in nanolipolomal vesicles. In last few decades, researcher have used herbal drug loaded nanoliposome for the treatment and management of a variety of cancers. Presently, a number of liposomal formulations are on the market for the treatment of cancer and many more are in pipe line. This review discusses about the tumor microenvironment, targeting mechanism of bioactive phytochemicals to the tumor tissue, background of nanoliposome, and the potential therapeutic applications of different bioactive phytochemicals loaded nanoliposome in cancer therapy.]]></description> </item><item><title><![CDATA[The Dual Specificity Role of Transcription Factor FOXO in Type 2-diabetes and Cancer]]></title><link>https://www.benthamscience.comarticle/92948</link><description><![CDATA[The FOXO (Forkhead box O) transcription factors are implicated in several signaling pathways and play a vital role in various cellular and physiological processes include for instance, ROS (reactive oxygen species) response, cell proliferation, regulation of programmed cell death, longevity, metabolism and cancer and regulation of cell cycle. In humans, the four FOXO family members are responsible for resemblance in their structure, regulation and functions. FOXO1 gene is highly expressed in adipose tissues and it affects the regulation of glycogenolysis and gluconeogenesis through insulin signaling. The gene of FOXO3 is highly expressed in the kidney, heart, spleen and brain and is characterized as diverse forkhead DNA-binding domain of transcription factors. The FOXO3 is a tumor suppressor gene and found to interact with p53, the trigger for apoptosis through BCl2 family genes and a regulator of Notch signaling pathway for the self-renewal of stem cells. Therefore, FOXOs remains to be a fascinating and potential target to acquire novel therapeutic approaches to cure cancer. This review will provide a comprehensive overview about the biology of FOXO proteins, which can be utilized for developing current therapeutic approaches to treat cancer.]]></description> </item><item><title><![CDATA[Magnetic Resonance Imaging of Nasopharyngeal Adenoid Hypertrophy in Children Following Bone Marrow Transplantation]]></title><link>https://www.benthamscience.comarticle/93235</link><description><![CDATA[Background: Nasopharyngeal adenoid hypertrophy (NAH) is a frequent incidental finding on head and neck imaging in children. </P><P> Objective: The study aimed to investigate magnetic resonance imaging (MRI) findings and prevalence of NAH after Bone Marrow Transplantation (BMT) in children with hemato-oncological diseases. </P><P> Methods: Between February 2013 and January 2018, BMT was performed in 202 pediatric patients. Forty-three patients (20 girl, 23 boy; age range, 1-19 years; mean age 9.4 years) who underwent at least two head and neck MRI before and after BMT were included in the study. Posttransplantation NAH (PTNAH) was considered when anterior-posterior (A-P) diameter of adenoid increased on post-BMT MRI relative to the previous MRI performed before BMT. Adenoid was evaluated for symmetry, cystic and septal content, signal intensity and contrast enhancement. </P><P> Results: Fourteen (32.5%) of 43 patients demonstrated PTNAH (7 boy, 7 girl; age range, 1-19 years; mean age, 10.5 years). Six (43%) of 14 patients were diagnosed with thalassemia. Six (50%) of 12 patients with thalassemia revealed PTNAH. The mean time intervals were 116 days and 213 days, respectively. The mean A-P diameter of adenoid was 5.2 mm before BMT which was 7.8 mm after BMT. All lesions were symmetric, isointense on T1-weighted (W), mild hyperintense on T2W and marked hyperintense on T2W TIRM images with slight contrast enhancement. Most of the lesions showed diffusion restriction and multiple longitudinal septa. Only one lesion revealed retention cysts. </P><P> Conclusion: NAH is a common finding after BMT in children. Awareness of imaging characteristics is important to prevent invasive procedures like biopsy and surgery.]]></description> </item><item><title><![CDATA[Phenolic Composition, Antioxidant and Cytotoxic Prospective of three Linum species: A Potential Source of Novel Anticancer Pharmacophores]]></title><link>https://www.benthamscience.comarticle/87568</link><description><![CDATA[The therapeutic potential of some Linum species has been reported previously. Nonetheless, several species of this genus warrant further scientific consideration. In this study, the phenolic composition, antioxidant activity (DPPH, phosphomolybdenum, iron chelating, hydroxyl radical and lipid peroxidation assays) and cytotoxicity effect (human rhabdomyosarcoma, human cervix carcinoma, and murine fibroblast cell lines) of ethyl acetate, methanol, and water extracts of three Linum species (Linum austriacum subsp. glaucescens, Linum hirsutum subsp. anatolicum, and Linum tenuifolium) were assessed. High performance liquid chromatography with diode-array detection (HPLC-DAD) analysis revealed the presence of ferulic acid, p-hydroxybenzoic acid, synapic acid, rutin, apigenin-glucoside, quercetin, luteolin, and naringenin in all the extracts. It was observed that the extracts (IC50 ranging from 42.07 to 51.66 &#181;g/mL) showed IC50 significantly (p<0.05) lower than ascorbic and gallic acid (> 1000 and 255.43 &#181;g/mL respectively) against lipid peroxidation. According to the American National Cancer Institute guidelines, the extracts showed low cytotoxicity (IC50 < 30 &#181;g/mL). However, the water extracts showed cytotoxicity effects (IC50 17.43&#177;0.13 to 28.12&#177;0.66 &#181;g/mL) against the studied cell lines as compared to the antineoplastic positive control (Cis-DDP). These findings support the use of these plants in the management of ROS mediated disorders and advocates for the need for further scientific evaluations to confirm the observed in vitro bioactivity. The cytotoxic potential coupled with the antioxidant property of the water extracts of these plant species is of particular interest which can open new avenues in the quest for novel anticancer drugs.]]></description> </item><item><title><![CDATA[Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms]]></title><link>https://www.benthamscience.comarticle/92852</link><description><![CDATA[Background: Chronic and non-communicable diseases such as non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis, obesity, diabetes, cardiovascular dysfunctions, renal insufficiency, alcoholism and other inflammation disorders often lead to severe organ damage. Fibrosis, on the contrary, is a complex phenomenon that may turn into critical conditions if not treated properly. Several biochemical pathways and signaling molecules, for instance, TGF-&#946;, ECM, MMPs, Collagens, MAPK, AP-1, SMAD and NF-&#954;B are responsible for the pathophysiology. In addition to these, inflammatory and pro-inflammatory cytokines are also blamed to be responsible in catalyzing fibrogenesis. </P><P> Methods: The information was basically searched using PubMed, Google Scholar and Science Direct and put all together to correlate fibrosis pathophysiology. Only recent publications were targeted to show protective roles of Resveratrol in animal studies and human subjects. </P><P> Findings: There is no effective treatment tactic available for curing fibrosis since multiple factors are associated with its progression; hence, it remains a big question to be answered by current healthcare associates. However, cell-based therapies have been showing quite effective approaches and are being suggested to counter fibrotic conditions. It is, however, highly expensive and complicated procedure and unfortunately, the availability of the strategy is limited worldwide. On the other hand, Resveratrol, a naturally occurring polyphenol which is largely being investigated in various animal models, cell cultures and human trials and thereby found highly potential in preventing measure against fibrosis. </P><P> Conclusion: Our current study, therefore, tries to establish some molecular pathways which are responsible for the progression of pro-fibrogenesis and fibrosis. Our findings would also explore the possible inhibitory role of Resveratrol alongside fibrosis.]]></description> </item><item><title><![CDATA[The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours]]></title><link>https://www.benthamscience.comarticle/86908</link><description><![CDATA[Background: Gliomas are brain tumours arising from the glia, the supportive tissue of the central nervous system (CNS), and constitute the commonest primary malignant brain tumours. Gliomas are graded from grade I to IV according to their appearance under the microscope. One of the most significant adverse features of high-grade gliomas is hypoxia, a biological phenomenon that develops when the oxygen concentration becomes insufficient to guarantee the normal tissue functions. Since tumour hypoxia influences negatively patient outcome and targeting hypoxia has potential therapeutic implications, there is currently great interest in imaging techniques measuring hypoxia. </P><P> Objectives: The aim of this review is to provide up to date evidence on the radiotracers available for measuring hypoxia in brain tumours by means of positron emission tomography (PET), the most extensively investigated imaging approach to quantify hypoxia. </P><P> Methods: The review is based on preclinical and clinical papers and describes the validation status of the different available radiotracers. </P><P> Results: To date, [F-18] fluoromisonidazole ([18F]FMISO) remains the most widely used radiotracer for imaging hypoxia in patients with brain tumours, but experience with other radiotracers has expanded in the last two decades. Validation of hypoxia radiotracers is still on-going and essential before these radiopharmaceuticals can become widely used in the clinical setting. </P><P> Conclusion: Availability of a non-invasive imaging method capable of reliably measuring and mapping different levels of oxygen in brain tumours would provide the critical means of selecting patients that may benefit from tailored treatment strategies targeting hypoxia.]]></description> </item></channel></rss>